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Abstract 
Natural killer (NK) cells can kill virus-infected cells without prior antigenic exposure, 
and are therefore important for controlling viral replication prior to the onset of adaptive immune 
responses. Primate NK cells express activating and inhibitory killer-cell immunoglobulin-like 
receptors (KIRs) that bind to specific major histocompatibility complex (MHC) class I 
molecules. The importance of KIR interactions with MHC class I in human immunodeficiency 
virus (HIV) pathogenesis is demonstrated by the association of select KIR and MHC class I 
genotypes with delayed progression to acquired immunodeficiency syndrome (AIDS). 
Simian immunodeficiency virus (SIV) infection of rhesus macaques is the primary model 
for AIDS, but few KIR ligands have been defined in this species. We identified Mamu-
B*007:01, -B*041:01, -B*058:02, and -B*065:01 as ligands for Mamu-KIR3DL01, one of the 
most polymorphic and commonly expressed KIRs in the rhesus macaque. We defined the MHC 
class I residues that are essential for this interaction, revealing an overlapping but distinct pattern 
of binding when compared to the recognition of ligands by human KIR3DL1, despite the lack of 
an orthologous relationship between these KIRs. 
Peptide presented by MHC class I ligands can affect binding to inhibitory KIRs. This 
effect is of particular interest during viral infection, which significantly alters the repertoire of 
peptides presented by MHC class I on infected cells. Using a cell line that presents distinct 
Mamu-A1*002-peptide complexes, we demonstrated that Mamu-KIR3DL05+ NK cells were 
inhibited by Mamu-A1*002 presenting some SIV peptides, but not others. Approximately one 
	  iv	  
third of the SIV peptides previously shown to bind to Mamu-A1*002 had an inhibitory effect 
upon Mamu-KIR3DL05+ NK cell activity. Among the inhibitory peptides were the three SIV 
CD8+ T cell epitopes that bind to Mamu-A1*002 with the highest affinity. Analysis of peptide 
variants revealed that residues 7 and 8 are most important for modulating interaction with 
Mamu-KIR3DL05. Peptide mixture experiments showed that the effect of an inhibitory peptide 
was dominant over a non-inhibitory peptide to prevent Mamu-KIR3DL05+ NK cell activation. 
These experiments suggest that inhibitory viral epitopes may prevent killing of infected cells by 
Mamu-KIR3DL05+ NK cells as a mechanism of immune evasion. 
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1.1 - The Immunodeficiency Viruses 
Human immunodeficiency virus (HIV) infection, if untreated, leads to acquired 
immunodeficiency syndrome (AIDS) and death (1). Approximately 35 million people worldwide 
are currently HIV-positive (2). HIV is a lentivirus of the retrovirus family. Other lentiviruses 
include simian immunodeficiency virus (SIV) (3) and feline immunodeficiency virus (FIV) (4). 
There are two types of HIV, HIV-1, which is closely related to SIV from chimpanzees (5), and 
HIV-2, which is closely related to SIV from sooty mangabeys (6). HIV-1 can be divided into 
three groups: M (main), O (outlier) and N (non-M or O). Of these groups, M is responsible for 
the worldwide epidemic of HIV infection. HIV-1 group M can be further subdivided into at least 
nine phylogenetically distinct clades: A, B, C, D, F, G, H, J, and K (7). These clades are 
geographically divided, such that clade B infection is most prevalent in North America and 
Europe, whereas clade C infection is the most common worldwide due to its prevalence in 
southern Africa (8).  
 
Immunodeficiency Virus Replication 
 Both HIV and SIV genomes are flanked by long terminal repeats (LTRs) and contain 
three main open reading frames (ORFs): Gag, Pol, and Env (Figure 1.1) (9). The Gag-Pol 
polyprotein can be cleaved into seven proteins: matrix, capsid, nucleocapsid, p6, protease, 
reverse-transcriptase, and integrase (10). Env is translated into the gp160 envelope protein that is 
cleaved to gp120 surface and gp41 transmembrane proteins. HIV and SIV also share five smaller 
ORFs: Vif, Vpr, Tat, Rev, and Nef  (9). However, HIV-1 and SIV differ with regards to two gene 
products: HIV-1 encodes Vpu, whereas SIV does not, and SIV encodes Vpx, whereas HIV-1 
does not. Vif, Nef, Vpu, and Vpx are accessory proteins that do not play direct roles in the viral 
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life cycle. Vif causes ubiquitination and degradation of the host restriction factor APOBEC3G 
that causes G to A hypermutation in the viral genome (11, 12). Nef downregulates several cell 
surface proteins to optimize the infected cell activation for viral production and to evade CD8+ T 
cell responses by MHC class I downregulation (13). In addition, Nef from SIVmac (14) and 
HIV-1 Vpu (15) downregulate tetherin, a host restriction factor that decreases viral release. 
Finally, SIV Vpx induces proteasomal degradation of SAMHD1, which is expressed in 
macrophages and dendritic cells and depletes the cellular pool of dNTPs (16, 17). The role of the 
remaining viral proteins involved in replication will be described below. 
 
Figure 1.1. Genome organization of HIV and SIV. Reproduced with permission from (9). © 
2012 Macmillan Publishers Ltd. 
 
 Infection with HIV or SIV begins with binding of gp120 to its CD4 receptor on the cell 
surface (10). This binding event causes a conformational change that allows gp120 binding to the 
coreceptor, usually CCR5, and subsequent fusion of viral and cellular membranes. Fusion 
releases the viral capsid into the host cytoplasm where partial viral uncoating occurs and reverse 
transcriptase produces dsDNA from the viral RNA template (10). This dsDNA genome is 
transported into the nucleus as part of the pre-integration complex including viral DNA, Vpr, 
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matrix, and integrase (18, 19). Integrase then inserts the viral genome into the host chromosome. 
Transcription of viral genes occurs via host machinery, and splicing leads to production of Rev, 
Tat, and Nef. Tat enhances viral transcription elongation (20), while Rev promotes nuclear 
export of unspliced mRNAs to allow translation of other viral proteins and incorporation of the 
full viral genome into new particles (21, 22). The Gag precursor protein binds to viral genomic 
RNA via the nucleocapsid region and accumulation of Gag and Gag-Pol at the cell membrane 
where Env is also localized leads to viral budding. Cleavage of Gag by protease after budding 
yields mature viral particles (10).  
 
1.2 - The Immunology of Immunodeficiency Virus Infection 
No cure or vaccine is yet available for HIV infection (23). Research into the pathogenesis 
of HIV, immune responses to the virus, and potential vaccine strategies is therefore of the 
highest priority. Rhesus macaque infection with simian immunodeficiency virus (SIV) also 
results in AIDS (3, 24) and is the primary animal model for AIDS research, particularly with 
respect to vaccine development. A highly-pathogenic clone of SIV, SIVmac239, is often used as 
the challenge strain in vaccine candidate studies (24).  
 
Clinical Course of HIV Infection 
The primary cell type infected by HIV and SIV is the CD4+ T cell, though macrophages 
(25-28), dendritic cells (DCs) (29, 30), astrocytes (31-33), and a subset of CD4-expressing NK 
cells (34) are also infected. In the weeks following infection, HIV viral load increases to a peak 
of about 107 viral copies per ml of blood and CD4+ T cell count decreases to about 500 cells per 
µL, compared to 1000 cells/µL in a healthy individual (35). The immune response cascade in 
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HIV infection begins with production of type I interferon (IFN) by DCs, followed by IL-15 
production that promotes the subsequent proliferation of natural killer (NK) cells (Figure 1.2) 
(36). The role of NK cells during acute infection is two-fold. Because NK cells can kill virus-
infected cells without prior antigen exposure and release chemokines that can block HIV 
coreceptor binding, they may limit viral replication prior to the onset of adaptive immune 
responses (37, 38). Furthermore, NK cells produce cytokines, such as IFN-γ, that can contribute 
to the development of a CD8+ T cell response even in the absence of CD4+ T cells as 
demonstrated in murine models (39). The peak of NK cells and CD8+ T cell responses correlates 
with a decrease in viral titer and rebound in CD4+ T cell count that marks the onset of clinical 
latency (40). The importance of such cellular responses is highlighted by the association of CD8+ 
T cell response with control of viral replication and delay of disease (41-43) and the increase in 
SIV replication in rhesus macaques following CD8-depletion, which removes both CD8+ T cells 
and NK cells (44).  
 
Figure 1.2. Cascade of immune responses in HIV infection. Described in text. Reprinted with 
permission from (36). © 2008 Blackwell Publishing Ltd. 
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Clinical latency can last for 10-15 years in HIV infection (45, 46), and 1-2 years 
following SIV infection of rhesus macaques (24, 47). During this time viral titer in the blood 
may be two to three logs lower than in the acute phase, but viral replication persists and causes 
CD4+ T cell turnover (48). The set-point at which the viral titer plateaus in the latent phase of 
infection is strongly associated with disease progression (49). Less than 1% infected individuals 
have extremely low viral set points, some below the level of detection by polymerase chain 
reaction (PCR) assay, and many of these patients can live without antiviral therapy and without 
progression to AIDS for decades (50-52). However, without treatment most patients eventually 
progress to AIDS, when CD4+ T cell counts decrease again and viral loads increase. CD8+ T cell 
responses also fail during this late chronic phase. These immunopathogenic effects of HIV 
infection lead to numerous infections in late-stage disease. AIDS is marked by opportunistic 
infections such as Pneumocystis jiroveci and candidiasis (53). There are also several AIDS-
associated cancers, including Kaposi’s sarcoma, caused by Kaposi’s sarcoma-associated 
herpesvirus, and Burkitt’s lymphoma, caused by EBV (54). Neurological symptoms, including 
dementia, and infections of the nervous system, such as cryptococcal meningitis, are also 
prevalent in chronic AIDS patients (55). 
The clinical course of HIV infection has changed dramatically with the introduction of 
antiretroviral drugs, beginning with azidothymidine (AZT) (56). Today inhibitors of viral 
protease, reverse transcriptase, integrase, and entry can be combined in a multi-drug regimen that 
completely suppresses viral replication below the limit of detection (57). However, such 
treatment is not sufficient to eradicate the virus, as viral load quickly rebounds after medication 
is halted. This rebound arises from viral reservoirs in long-lived cells containing latent integrated 
provirus. The main population of cells harboring the latent virus is resting memory CD4+ T cells 
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(57-59), which may live for years without being activated - an event that would cause subsequent 
viral gene expression and cell death. Yet this CD4+ T cell population does not account for all 
virus that rebounds after cessation of treatment, suggesting the existence of other reservoirs (60). 
Monocytes, DCs, and hematopoietic stem cells may be among these other reservoirs (61). It had 
been calculated that due to the slow turnover of these reservoir cells, complete viral suppression 
by antiretroviral treatment for 73 years would be sufficient to eliminate all viral reservoirs (62). 
Yet recent studies suggest that the amount of replication-competent latent virus was 
underestimated in this calculation and full clearance would take even longer (63). Clearly drug 
treatment alone will not be sufficient to cure HIV, but there is some hope that drug treatment in 
combination with reactivation of viral reservoirs and promotion of immune responses may lead 
to a functional cure (64). Better characterization of the regulation of NK cell and CD8+ T cell 
activity may inform strategies to promote killing of infected cells that would be useful in this 
context.  
 
Immune Responses to Immunodeficiency Viruses 
 CD8+ T cell responses. CD8+ T cell responses are critical for controlling HIV and SIV 
viral replication and are associated with delayed progression to disease in untreated individuals 
(41-44). HIV-specific CD8+ T cells recognize infected cells that present MHC class I-bound HIV 
epitopes and kill them by releasing perforin and granzyme (65, 66). CD8+ T cells also secrete 
chemokines that may inhibit viral entry (67). Nef-mediated downregulation of major 
histocompatibility complex (MHC) class I (68) and viral sequence variation to escape TCR 
recognition are the main mechanisms by which the virus evades this response. CD8+ T cell 
responses to certain Gag epitopes are associated with positive disease outcome (69, 70). MHC 
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class I molecules associated with delayed disease progression, including Mamu-A1*001, -B*008 
and -B*017 in rhesus macaques (71-73) and HLA-B*27 and -B*57 in humans (74, 75), may 
present viral epitopes that elicit a particularly effective CD8+ T cell response from which the 
virus cannot escape without great fitness cost (76-80). Despite the effectiveness of CD8+ T cells 
in controlling acute viral infection, CD8+ T cells can become exhausted during chronic HIV 
infection and upregulate when PD-1, correlating with disease progression (81). In contrast, non-
progressors maintain strong CD8+ T cell proliferative capacity despite long-term HIV infection 
(82). The CD8+ T cell response therefore seems critical for initial viral control but may become 
less effective as proliferative capacity is lost in progressive HIV infection, during which high 
levels of viral replication can persist despite prevalent HIV-specific CD8+ T cell responses (83-
85). 
 CD4+ T cell responses. The efficacy of HIV-specific CD4+ T cell responses is 
complicated by the fact that these cells are also the targets of HIV infection. HIV-specific cells 
are more highly infected than other CD4+ T cells, and any antigen-induced proliferative response 
would create more targets for viral infection (86). Likewise, the association of CD4+ T cell 
function with elite control (87) may simply be a result of decreased infection of these cells, a 
hypothesis supported by the finding that patients on antiretroviral therapy also have greater CD4+ 
T cell function (88). Still, several CD4+ T cell functions play a role in developing effective 
responses to HIV: helper T cells enhance CD8+ T cell responses (89), T follicular helper cells 
promote B cell antibody production (90), and cytolytic CD4+ T cells kill virus-infected cells (91).  
 Antibody responses. Although antibodies emerge in the weeks following HIV infection, 
neutralizing antibodies are not generally protective. Neutralizing antibodies are actually less 
common in HIV non-progressors than in viremic individuals (92), yet a small subset of 
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individuals produces broadly neutralizing antibodies during controlled infection (93). These 
antibodies are capable of neutralizing a wide variety of HIV strains, and as such may provide a 
protective effect not afforded by other antibodies. Antibodies targeting the CD4 binding site of 
gp120, variable loops of gp120, or a membrane-proximal region of gp41 are the most effective 
(94). Furthermore, non-neutralizing functions of antibodies may play a role in minimizing viral 
acquisition or replication, particularly in the case of antibody-dependent cell-mediated 
cytotoxicity (ADCC). Protection after vaccination with live-attenuated SIV is associated with 
ADCC activity (95). Envelope glycosylation, which prevents antibody recognition of much of 
the viral envelope, is a critical viral immune evasion strategy (96, 97). In addition, the high 
degree of antigenic variation makes it difficult to produce an antibody that can recognize all 
variants of the virus found within an individual, leading to quick emergence of resistance to 
mounted responses.   
 Natural killer cell responses. NK cells are primarily activated to kill virus-infected cells 
and tumor cells that have low expression of MHC class I molecules that act as ligands for NK 
cell inhibitory receptors. Because MHC class I is downregulated by Nef in HIV and SIV, 
infected cells are vulnerable to killing by NK cells. However, HIV selectively downregulates 
HLA-A and -B, but not HLA-C, which is largely responsible for inhibiting NK cell function in 
humans through interaction with inhibitory KIR2D molecules (98). This selective 
downregulation allows evasion of HLA-A- and -B-restricted CD8+ T cell responses and 
maintenance of HLA-C expression for inhibition of NK cells. However, rhesus macaques do no 
express orthologues of either HLA-C or KIR2D, and although Nef selectively downregulates 
some Mamu-A and -B molecules (99), there is no evidence to suggest that this selective 
downregulation maintains NK cell inhibition. In addition to being activated by loss of MHC 
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class I-mediated inhibitory signals, NK cells may also be activated by the upregulation of 
activating receptor ligands on infected cells (100). Finally, NK cells can be activated to kill cells 
that bind antibody that in turn binds CD16 on the NK cell. This interaction is the functional 
mechanism behind the ADCC effect of non-neutralizing antibodies described above. The 
regulation of NK cells and their role in HIV and SIV infection will be discussed in greater detail 
in the following sections. 
 
1.3 - Natural Killer Cells and Killer-cell Immunoglobulin-Like Receptors 
 NK cells are essential for controlling many viral infections (101-103). NK cells are 
regulated by activating and inhibitory receptors on the cell surface that allow them to recognize 
some virus-infected and tumor cells without previous exposure to a given antigen. The balance 
of signals from NK receptors binding ligands on a target cell determines whether an NK cell will 
become activated (104). Upon activation, an NK cell can kill target cells by releasing cytotoxic 
granules containing perforin and granzyme or through expression of Fas-L and TRAIL (105). 
NK cells may also produce cytokines, including interferon (IFN)-γ (106), and β-chemokines, 
including CC-chemokine ligand 3 (CCL3), CCL4, and CCL5 (37, 107, 108). NK cells are 
particularly important in early control of viral infection prior to development of antigen-specific 
adaptive immune responses (36). 
 
NK Cell Subsets  
Human NK cells are divided into different functional subsets based on expression of 
CD16 and CD56. CD16+CD56dim cells are more cytotoxic and produce limited cytokine (109), 
whereas CD16-CD56bright NK cells are thought to play a regulatory role (110). However, rhesus 
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macaque NK cells differ from those in humans, as most do not express CD56 (111). Instead, a 
rare population of CD56+ NK cells in rhesus macaques correspond to the CD56bright population 
from humans, expressing lymph node homing markers CCR7 and CD62L and low levels of 
granzyme B and perforin (Figure 1.3).  A rhesus macaque CD16+CD56- NK cell subset 
corresponds to the CD16+CD56dim human population, lacking expression of lymph node homing 
markers and maintaining relatively high expression of granzyme B, perforin, and β-chemokines 
(112-114). A third population of CD16-CD56- NK cells appear to be an intermediate stage 
between the other two subsets, which is consistent with the hypothesis that rhesus macaque 
CD56+ and human CD56bright NK cells are immature (115).  
 
Figure 1.3. Human and rhesus macaque NK cell subsets. (A) Human NK cell subsets described 
by CD56bright or CD56dim expression have distinct functional capacities and expression of several 
cell surface markers. (B) Rhesus macaque NK cell subsets described as CD56+ and double 
negative (DN) are less differentiated than mature CD16+ NK cells. Each subset has distinct cell 
surface markers and functional capacity. Reproduced under Creative Commons Attribution 
License from (114).  
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FIGURE 2 | Comparison of rmNK and hNK cell subpopulations.Markers
characterizing the distinct NK cell subpopulations are illustrated with an
emphasis on molecules either indicating a more primitive stage of
hematopoietic differentiation or an effector cell profile. (A) Human CD56bright
and CD56dim NK cells are shown. (B) Rhesus CD56+, DN, and CD16+ NK cell
subsets are shown.
et al., 2003), although this gating strategy excludes the CD56+ and
DN rmNK cell subpopulations, andmay have limited the authors’
ability to accurately assess the effects of SIV infection on the full
repertoire of rmNK cells.
Although NK cells from chronically HIV- or SIV-infected
donors display a hyper-activated state, their capacity to respond to
PMA and ionomycin is diminished (Azzoni et al., 2002; Labonte
et al., 2006). Furthermore, studies have demonstrated a dra-
matic skewing of NK cell subpopulations in peripheral blood
during SIV and HIV infection. HIV infection was associated
with a decrease of CD56dim NK cells and an increase of the
CD56−CD16+ NK cell subset (Alter et al., 2005; Mavilio et al.,
2005b; Hong et al., 2010a,b), whereas SIV-infected macaques dis-
played an expansion of DN and CD16+ NK cells (Reeves et al.,
2010). Interestingly, both HIV and SIV infection induced a loss of
CCR7-expressing CD56bright and CD56+ cells, respectively, with-
out affecting the frequencies of cells expressing CD62L (Reeves
et al., 2010; Hong et al., 2012). This perturbation was further-
more accompanied by an increased expression of granzyme B
and perforin and elevated degranulation in response to MHC
class I-devoid tumor cells (Mantegani et al., 2009). Importantly,
there seems to be an inverse relationship between the severity
of immune activation and/or viral load and the impact of viral
infection on NK cells, as evidenced in natural host SIV infec-
tion in sooty mangabeys (Pereira et al., 2008) or non-viremic
HIV-patients (Vieillard et al., 2010). Taken together, these studies
provide solid evidence for SIV-induced perturbations in rmNK
cells similar to what has been described in chronic HIV infection.
NON-HUMAN PRIMATE STUDIES SHED LIGHT ON NK CELLS
IN TISSUES
Whereas most hNK studies have focused on NK cell subsets from
peripheral blood, much less is known about NK cells in tissues.
The complexity and heterogeneity of hNK cells residing in vari-
ous organs, such as uterus, brain, spleen, liver, pancreas, and skin,
as well as various mucosal tissues, including the gut, is an area
of research that is garnering increasing interest (Shi et al., 2011).
For obvious reasons, research is hindered by the significant limi-
tations in obtaining human tissue samples. Here, we highlight one
example of how studies on tissue-residing NK cells in non-human
primates may lead to a better understanding of human diseases.
A novel IL-22- and IL-17-producing NKp44+ hNK cell sub-
set was recently discovered in human and mouse mucosal-
associated lymphoid tissues (Cella et al., 2009; Crellin et al.,
2010). Unlike conventional NK cells, these lymphocytes do
not display cytolytic activity but instead seem to be cru-
cial for maintaining the integrity of epithelial tissues. Since
HIV and SIV are predominantly transmitted and replicate
in gut-associated lymphoid tissues (GALT), we and oth-
ers sought to explore the role of IL-22-producing NK cells
in SIV infection. SIV infection was associated with a sub-
stantial loss of IL-17- and IL-22-producing lymphocytes,
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Regulation of NK Cell Activity 
In primates, NK cell receptors that recognize MHC class I ligands belong to two families: 
killer-cell immunoglobulin-like receptors (KIRs) and killer lectin-like receptors (KLRs). KLRs 
in primates include CD94/NKG2 heterodimers that recognize HLA-E in humans and are 
inhibitory, in the case of NKG2A, or activating, in the case of NKG2C (116-118). Another KLR, 
NKG2D, is a distinct type of activating receptor that recognizes stress-induced MHC class I-like 
molecules such as MICA/B and ULBP (119, 120). Expression of these NKG2D ligands can be 
induced by some viral infections, leading to NK cell activation. HIV evades this response 
through Vpu- and Nef-mediated downregulation of NKG2D ligands (121, 122). Unlike KLRs 
that recognize relatively conserved MHC class I and MHC class I-like molecules, KIRs 
specifically recognize highly polymorphic ligands HLA-A, -B, and -C in humans, and Mamu-A 
and -B ligands in rhesus macaques. Correspondingly, KIR are by far the most polymorphic of the 
NK cell receptors (123). In addition to being expressed on NK cells, KIRs are also expressed on 
a subset of CD8+ T cells (124) and may therefore modulate both NK cell and cytolytic T cell 
responses. Notably, mice do not express KIRs but instead use Ly49, a KLR, as the primary 
polymorphic receptor for MHC class I ligands (125). 
 
Figure 1.4. KIR structure. Graphic representation of inhibitory (L) and activating (S) KIRs with 
two (2D) or three (3D) extracellular Ig domains. 
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KIRs are type I transmembrane proteins that may have two (2D) or three (3D) 
extracellular immunoglobulin (Ig)-like domains (126, 127), and a short (S) or a long (L) 
cytoplasmic tail (128), as diagrammed in Figure 1.4. The Ig-like domains are D0, found in 
KIR3D molecules only, D1, and D2. Long cytoplasmic tails belong to inhibitory KIRs and 
contain two immunoreceptor tyrosine-based inhibitory motifs (ITIMs). In contrast, short 
cytoplasmic tails belong to activating KIRs, which associate with an adaptor molecule that has 
an immunoreceptor tyrosine-based activating motif (ITAM) in its cytoplasmic tail (128). Human 
KIR3DS1 associates with the DAP12 adaptor through a trasmembrane lysine residue, but rhesus 
macaque activating KIRs lack this lysine and the adaptor for these molecules is unknown. Upon 
activating receptor engagement, ITAMs in the adaptor protein are phosphorylated by Src kinases, 
which leads to the recruitment of Syk or ZAP70 and the initiation of a phosphorylation cascade 
leading to cell activation (129, 130). In contrast, after inhibitory receptor binding, ITIMs recruit 
SHP-1 and SHP-2 phosphatases, dephosphorylating components of the ITAM cascade to prevent 
activation (131). Thus, a balance of the two signals determines NK cell activity. 
Given the balance of signals regulating NK cell activity, NK cell activation can result 
from a loss of inhibition or an increase in activating signal. When interacting with a healthy 
autologous cell, NK cells are inhibited by binding of inhibitory receptors to self-MHC class I 
molecules (Figure 1.5A). To ensure self-tolerance, NK cells stochastically express KIR during 
development until there is sufficient expression of inhibitory receptors that recognize self-MHC 
class I molecules to prevent killing of autologous cells (132). NK cells that do not become 
sufficiently inhibited remain anergic. Once KIR expression has been established for a developing 
NK cell, expression is stably maintained by DNA methylation (133). This process creates a 
heterogeneous population of NK cells, some of which express multiple KIRs, that are inhibited 
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when interacting with healthy autologous cells. However, during tumor progression or viral 
infection, MHC class I expression on autologous cells may decrease (13, 134). These conditions 
can lead to NK cell activation by “missing self” or the lack of inhibition by autologous MHC 
class I molecules (Figure 1.5B). Alternatively, NK cells can be activated by excessive activating 
receptor engagement, even under conditions when inhibitory signals remain present (135, 136). 
Activating ligands that may be upregulated on virus-infected cells include NKG2D ligands 
MICA/B and ULBP, which are induced by stress (119, 120). Some NK cell activating receptors 
also detect specific viral gene products, such as NKp46, which binds to influenza hemagglutinin 
(HA) (137), and Ly49H in mice, which recognizes the murine cytomegalovirus protein m157 
(138). NK cell activation by virus-infected cells results from a combination of these signals: loss 
of MHC class I recognition by inhibitory receptors, increased recognition of stress-induced 
ligands by activating receptors, and in some cases recognition of viral proteins by activating 
receptors. 
 
Figure 1.5. NK cell tolerance and missing self. Expression of self-MHC class I molecules 
prevents lysis by autologous NK cells. Decreased expression of these inhibitory receptor ligands 
can lead to “missing self,” NK cell activation, and lysis. Reproduced with permission from (139). 
© 2005 Nature Publishing Group. 
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KIR Ligands in Humans and Rhesus Macaques 
The ligands for many human KIRs have already been identified and can be defined in 
part by determinant residues in the MHC class I α1 domain. Human KIR2DL recognize HLA-C 
molecules that fall into two different categories. KIR2DL1 binds allotypes that have an 
asparagine at residue 77 and a lysine at residue 80, whereas KIR2DL2 and KIR2DL3 bind 
allotypes that have a serine at residue 77 and an asparagine at residue 80 (140). HLA-B 
molecules can also be divided into two groups based on residues in a similar region: Bw4 
molecules have an NLR(I/T)ALR motif at residues residues 77-83 in the α1 domain  and Bw6 
molecules have an SLRNLRG motif at the same position. Human KIR3DL1 interacts with HLA-
A and -B molecules that have a Bw4 motif (141, 142). In contrast, KIR recognition of HLA-B 
Bw6 molecules has not been observed. Unlike human KIR ligands, few rhesus macaque KIR 
ligands have been defined. Prior to the work included in this dissertation, Mamu-KIR3DL05 
interaction with Mamu-A1*002 had been identified by binding and cellular assays (143, 144). 
Additional binding data indicates that Mamu-A1*001 and -A3*13 are also ligands for Mamu-
KIR3DL05, and that Mamu-KIR3DLW03 binds Mamu-A1*001 and -A1*011 (143). Of note, 
though human KIR recognition of Bw6 molecules has not been demonstrated, these Mamu-
KIR3D ligands include the Bw6 molecules Mamu-A1*002 and -A3*13. Although these 
interactions with inhibitory KIRs have been verified by binding assays, with the exception of a 
recent crystal structure of KIR2DS2 in complex with HLA-A*11 (145), such verification has 
been difficult for activating KIR because many exhibit low ligand binding or no detected binding 
(146). KIR3DS1, for example, is an inhibitory KIR with extracellular homology to KIR3DL1 
and would therefore be expected to bind similar ligands. Indeed, in cellular assays KIR3DS1+ 
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NK cells are activated by target cells expressing Bw4 molecules that are ligands for KIR3DL1, 
but binding data to confirm this interaction has not been conclusive (147-149).  
 
Determinants of KIR Recognition 
Residues in the α1 and α2 domains of ligand MHC class I molecules are determinants of 
KIR recognition. Contact residues have been determined by crystals structures of human KIR-
ligand complexes: KIR2DL2 with HLA-Cw3 (150); KIR2DL1 with HLA-Cw4 (151); KIR2DS2 
with HLA-A*11 (145); and KIR3DL1 with HLA-B*57 (152). Consistent with other KIR 
structures, KIR3DL1 binds over the carboxy-terminus of the HLA-B*57 peptide-binding cleft, 
contacting both the α1 and α2 helices (Figure 1.6). As previously mentioned, recognition by 
KIR3DL1 is highly dependent on the Bw4 motif in the ligand α1 domain. The isoleucine at 
position 80 and the arginine at position 83 in this region are contacted by KIR3DL1 D1 and D2, 
respectively. Mutational analysis revealed that alanine substitution at either of these positions 
abrogated KIR3DL1 recognition, and that additional contact residues in the α2 helix are also 
essential for binding. KIR3DL1 also contacts the MHC class I-bound peptide. A leucine at 
position 166 in the D1 domain contacts the serine at position 8 of the HLA-B*57-bound peptide.  
Similarly, KIR2DL2 and KIR2DS2 also contact residue 8 in the HLA-bound peptides of their 
respective ligands (145, 150). Substitution at this peptide position can drastically alter the 
affinity of KIR binding, demonstrating the peptide selectivity of this interaction. 
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Figure 1.6. Crystal structure of human KIR3DL1 in complex with HLA-B*57. Orthogonal view 
of KIR3DL1 binding over the C-terminus of peptide presented by HLA-B*57. KIR3DL01 β-
strands are labeled in (a). KIR3DL1 D0, D1, and D2 are colored yellow, blue, and orange, 
respectively. HLA-B*57, peptide, and β2m are colored green, purple, and grey, respectively. 
Reprinted with permission from (152). © 2011 Macmillan Publishers Ltd. 
 
The peptides presented by MHC class I ligands affect recognition by inhibitory KIR. 
Human KIR3DL1 binds HLA-A*24 and -B*27 tetramers folded with some peptides but not 
others (142, 153, 154). Recognition by this KIR and affected by alterations at position 7 or 8 in 
HLA-B*27-bound peptides and the hierarchy of preferred peptides varies among different 
KIR3DL1 allotypes. Like KIR3DL1 binding, both KIR2DL1 and KIR2DS1 binding to HLA-
Cw4 are altered by changes in residue 8, and to a lesser extent residue 7, of the presented peptide 
(155, 156), corresponding to the closer proximity of residue 8 sidechain to KIR2DL1 in the 
complex crystal structure (151). Furthermore, an antagonistic peptide presented by HLA-C can 
cause activation of NK cells by loss of KIR2DL2- and KIR2DL3-mediated inhibition (157). This 
peptide selectivity has implications during conditions of cell stress or viral infection, wherein the 
array of peptides presented on the cell surface may change dramatically (158, 159). In some 
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cases, presentation of viral peptides may lead to NK cell activation. HLA-Cw7 presenting 
peptides derived from glutamic acid decarboxylase or coxsackie virus, but not other self-peptides 
tested, could be killed by a KIR2DL2-expressing NK cell clone (160). These data highlight that 
KIR may be responsible not only for the recognition of “missing self” due to downregulated 
MHC class I, but also for recognition of “altered self” in the form of presentation of stress-
induced or viral peptides. 
  
1.4 - NK Cells in Immunodeficiency Virus Infection 
 While some NK cell subsets may become infected during HIV infection, NK cells are 
clearly more than just sites of viral replication during immunodeficiency virus infection. The 
vital role that NK cells may play in early infection is highlighted by the fact that the initial 
decrease in viral load is prior to the onset of adaptive immune responses and may therefore be an 
effect of NK cell control (36). Furthermore, an increase in SIV replication in infected animals 
was observed following depletion of CD8+ cells, which includes both CD8+ T cells and NK cells 
in rhesus macaques, thereby demonstrating the importance of one or both of these responses for 
SIV control (44).  Transient depletion of CD16+ cells in rhesus macaques during primary and 
chronic SIV infection attempted to specifically assess the importance of NK cells for SIV control 
and saw a trend toward higher viral load in primary infection, but no effect of depletion during 
chronic infection (161, 162). However, CD16 is not a true NK cell marker in rhesus macaques, 
and CD16- NK cell subsets are prevalent in the gut mucosa where much of SIV replication takes 
place (113). Moreover, CD16 is also expressed by monocytes, further complicating interpretation 
of these depletion results (163). Further studies with a more NK cell-specific depleting antibody 
will be necessary to determine the effect that these cells have on SIV control. 
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Changes in NK cells During Immunodeficiency Virus Infection 
 Many functional changes have been observed in NK cells during HIV and SIV infection. 
The frequencies of NK cell subsets are often altered. Broadly, decreasing lytic function of NK 
cells has been associated with AIDS and duration of HIV infection, and has been proposed as a 
prognostic indicator of progression to disease (164, 165). A decrease in CD56+ NK cells, and a 
concomitant expansion of CD56dimCD16+ NK cells occurs during acute HIV infection, followed 
by depletion of the CD16+ NK cells as HIV progresses and increased anergy in the remaining 
cells of this subset (164, 166-168). The impairment of NK cells in chronic HIV infection further 
extends to their ADCC function (169, 170) and cytokine secretion (171), whereas chemokine 
secretion is unaffected by infection (108). Although it has been suggested that HIV infection of 
NK cells contribute to these imbalances, they are equally cytotoxic as uninfected NK cells and 
there are therefore likely other mechanisms at play (172, 173). Notably, HIV controllers maintain 
highly-functional NK cells, which may contribute to sustained control of viral replication (174).  
In addition to changes in the frequency of NK cell subsets, immunodeficiency virus 
infection can alter NK cell trafficking. In SIV infection, α4β7 expression on NK cells increases 
and CCR7 expression decreases, increasing trafficking to the gut mucosa and decreasing lymph 
node homing, respectively (175). During SIV infection, CD56+ NK cells become redistributed to 
the gut, whereas CD16+ and CD16-CD56- NK cells are more prevalent in the periphery (113). 
This observation suggests that the depletion of CD56+ NK cells observed during acute HIV 
infection may be due in part to a redistribution of these cells to different tissues. The function of 
CD56+ NK cells changes during SIV infection, with decreased IFN-γ production in the α4β7+ 
subset and increased expression of the degranulation marker CD107a, indicating greater 
cytotoxicity, on all CD56+ NK cells (175). CD16+ and CD16-CD56- NK cells also show 
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increased markers of cytotoxicity during chronic SIV infection, but have decreased cytokine 
expression (113).  
 
KIR and MHC Class I in Immunodeficiency Virus Infection 
 Genetic evidence suggests that KIR-MHC class I interactions play an important role in 
the prognosis for HIV infection. KIR3DL1 or KIR3DS1 coexpression with their HLA-Bw4 
ligand is associated with delayed progression to AIDS (176, 177), as is an increase in copy 
number of these KIR (178). These genotypes are furthermore implicated in the maintenance of a 
subset of gut mucosal NK cells in controllers (179). KIR3DS1 and ligand coexpression is also 
associated with decreased opportunistic infections, but not cancers, later in disease (180). 
Furthermore, these same genotypes have been associated with individuals who have been 
exposed to HIV but have not become infected, suggesting that the protective effect of these 
potent NK cells may extend to viral acquisition (181). 
While it is surprising that both an activating and an inhibitory KIR could have the same 
effect, functional studies have shown that both populations expand during acute HIV infection in 
individuals who express the ligand for these KIRs, perhaps indicating KIR-mediated activation 
of these cells (182). Furthermore, KIR3DS1+ NK cells suppress HIV replication more effectively 
and KIR3DL1+ NK cells secrete more β-chemokines that inhibit viral entry in response to HIV-
infected autologous ligand-expressing cells than KIR3DL1-KIR3DS1- NK cells (148, 183). 
These results show that KIR3DS1+ and KIR3DL1+ NK cells from individuals expressing ligands 
for these KIR are selectively activated in response to HIV-infected autologous cells. One cause 
of KIR3DL1+ NK cell activation could be that a common escape mutation in a CD8+ T cell 
epitope bound by HLA-B*57, a KIR3DL1 ligand, prevents recognition by KIR3DL1 (184). This 
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subset of NK cells may therefore be activated to kill cells infected with viral variants that escape 
CD8+ T cell responses. In rhesus macaques KIR have also been associated with NK cell function 
during SIV infection. The copy number for activating KIR has been associated with SIV control 
(185), whereas the inhibitory Mamu-KIR3DL05 has been associated with higher viral loads 
(186). Additionally, activating KIR2DL4 copy number has been associated with maintenance of 
CD4+ T cells and increased IFN-γ production from NK cells during acute SIV infection (187). 
Together these genetic associations and functional data show that KIR-expressing subsets of NK 
cells have distinct functional activity during HIV and SIV infection, and may affect the degree of 
viral replication and rate of progression to disease. 
 Perhaps the most conclusive evidence for the importance of KIR-MHC class I 
interactions and NK cells during immunodeficiency virus infection is the detection of KIR-
associated footprints in HIV, which suggest KIR-mediated immune pressure. Polymorphisms in 
HIV were significantly associated with KIR expression for several activating and inhibitory KIR 
(188). Two of the mutations were in overlapping coding regions of Vpu and Env, and when 
cloned into HIV, this variant was more capable of replicating in the presence of KIR2L2+ NK 
cells than was wild-type virus. Furthermore, KIR2DL2 binding to infected cells was increased by 
these mutations. It should be noted that CD8+ T cells may also express KIR, and mutations that 
cause NK cell inhibition might also inhibit CD8+ T cell killing via inhibitory KIR interactions 
(189, 190). The effect of viral mutations upon KIR binding may extend to other KIR as well, as 
naturally-occuring epitope variants affect KIR2DL2 binding to HLA-Cw*0102 ligands and 
KIR3DL1 binding to HLA-B*57 (184, 191), such that escape from CD8+ T cell responses may 
increase the ability of NK cells expressing these inhibitory KIR to respond to virus-infected 
cells. In rhesus macaques, the binding of Mamu-KIR3DL05 to its ligand, Mamu-A1*002, is also 
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affected by SIV peptides. Mamu-A1*002 tetramers folded with some SIV peptides, but not 
others, bind Mamu-KIR3DL05 (Figure 1.7) (144). Mamu-KIR3DL05 interaction with Mamu-
A1*002 folded with Gag71-79 GY9 is strong enough to stain this KIR on primary rhesus macaque 
NK cells, which has not been seen with any other tetramers tested.  
 
Figure 1.7. Peptide selectivity of Mamu-KIR3DL05 binding to Mamu-A1*002. Jurkat cells 
transfected with an HA-tagged Mamu-KIR3DL05 construct were stained with Mamu-A1*002 
tetramer folded with different SIVmac239 CD8+ T cell epitopes. Mamu-A1*002 tetramers folded 
with Gag71-79 GY9, more weakly to tetramers folded with Nef159-167 YY9 or Env788-795 RY8, and 
did not bind Mamu-A1*002 folded with Vif89-97 IW9. Reprinted under the Creative Commons 
Public Domain from (144). 
 
1.4 - Scope of this Dissertation 
This dissertation develops a further understanding of KIR-MHC class I interactions in the 
rhesus macaque. Study of rhesus macaque KIR and NK cell populations is severely restricted 
because few KIR ligands have been identified and few staining reagents are available to identify 
KIR-expressing NK cell subsets. In the second chapter of this dissertation, I have identified four 
Bw4 molecule ligands of the inhibitory Mamu-KIR3DL01. Mutational analysis revealed that 
many of the contact residues are maintained between human KIR3DL1 and Mamu-KIR3DL01 
recognition, despite the lack of an orthologous relationship between these KIR. This work has 
also identified the binding specificity of a pan-human-KIR2D antibody that stains most allotypes 
of Mamu-KIR3DL01, thereby doubling the number of staining reagents available for specific 
rhesus macaque KIRs and enabling further studies of the frequency of KIR-expressing NK cell 
populations in vivo. 
Figure 4. Polymorphisms in the D0 and D1 domains of Mamu-KIR3DL05 modulate the avidity and peptide-selectivity of binding to
Mamu-A1*00201. (A) Jurkat cells were transfected with HA-tagged Mamu-KIR3DL05 expression constructs, and stained the next day with APC-
conjugated Mamu-A1*00201 tetramers (Gag71-79 GY9, Env788-795 RY8, Nef159-167 YY9 or Vif89-97 IW9), followed by a PE-conjugated antibody to the HA
tag. Quadrant gates were set using empty vector-transfected controls stained with tetramer and antibody to the HA tag. (B) An alignment comparing
the predicted amino acid sequences of the D0, D1 and D2 domains for seven different Mamu-KIR3DL05 alleles. Positions of amino acid identity with
the consensus sequence are indicated by a period. The shaded regions correspond to loops predicted to contact surfaces of the peptide-MHC class I
complex [37]. The plus signs beneath the alignment indicate unique residues in the D1 domain of mmKIR3DL05x that coincide with, or are
immediately adjacent to, predicted MHC class I-contact loops.
doi:10.1371/journal.ppat.1001316.g004
Peptide-Selective Binding of KIR3DL to MHC Class I
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Figure 4. Polymorphisms in the D0 and D1 domains of Mamu-KIR3DL05 modulate the avidity and peptide-selectivity of binding to
Mamu-A1*00201. (A) Jurkat cells were transfected with HA-tagged Mamu-KIR3DL05 expression constructs, and stained the next day with APC-
conjugated Mamu-A1*00201 tetramers (Gag71-79 GY9, Env788-795 RY8, Nef159-167 YY9 or Vif89-97 IW9), followed by a PE-conjugated antibody to the HA
tag. Quadrant gates were set using empty vector-transfected controls stained with tetram r and antibody to the HA ag. (B) An alignment comparing
the predicted amino acid sequences of the D0, D1 and D2 domains for seven different Mamu-KIR3DL05 alleles. Positions of amino acid identity with
the consensus sequence are indicated by a period. The shaded regions correspond to loops predicted to contact surfaces of the peptide-MHC class I
complex [37]. The plus sig s beneath the alignment indicate unique residues in the D1 domain of mmKIR3DL05x that coincide with, or are
immediately adjacent to, predicted MHC class I-contact loops.
doi:10.1371/journal.ppat.1001316.g004
Peptide-Selective Binding of KIR3DL to MHC Class I
PLoS Pathogens | www.plospathogens.org 6 March 2011 | Volume 7 | Issue 3 | e1001316
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In the third chapter of this dissertation, I have investigated the functional relevance of the 
peptide preference of Mamu-KIR3DL05 recognition of Mamu-A1*002. A cytotoxicity assay 
was developed to evaluate Mamu-KIR3DL05+ NK cell killing of peptide-pulsed cells that 
express distinct Mamu-A1*002-peptide complexes on the cell surface. This assay enabled study 
of NK cell inhibition in response to cells expressing the same MHC class I molecule but 
presenting different peptides. Approximately one-third of the previously identified SIV peptides 
that bind Mamu-A1*002 inhibited Mamu-KIR3DL05+ NK cell activity. Peptide variants 
revealed that bulky residues at position 7 or 8 of the Mamu-A1*002-presented peptide could 
abrogate inhibition of Mamu-KIR3DL05+ NK cells and that suppression of this NK cell 
population by an inhibitory peptide is dominant over a non-inhibitory peptide when presented as 
part of a peptide mixture. These results, together with the diminished ability of Mamu-
KIR3DL05+ NK cells to suppress viral replication in autologous cells from Mamu-A1*002+ 
animals, suggests that such inhibitory epitopes may evade the immune response of the Mamu-
KIR3DL05+ NK cell subset. 
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Chapter 2 
KIR3DL01 Recognition of Bw4 Ligands in the Rhesus Macaque: 
Maintenance of Bw4 Specificity since the Divergence of Apes and 
Old World Monkeys 
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2.2 - Abstract 
The identification of MHC class I ligands for rhesus macaque KIRs is fundamental to our 
basic understanding of KIR and MHC class I co-evolution and to the study of NK cell responses 
in this non-human primate model for AIDS and other viral diseases. Here we show that Mamu-
KIR3DL01, which is expressed by approximately 90% of rhesus macaques, recognizes MHC 
class I molecules with a Bw4 motif. Primary NK cells expressing Mamu-KIR3DL01 were 
identified by staining with a mAb herein shown to bind Mamu-KIR3DL01 allotypes with an 
aspartic acid at position 233. The cytolytic activity of Mamu-KIR3DL01+ NK cells was 
suppressed by cell lines expressing the Bw4 molecules Mamu-B*007:01, -B*041:01, -B*058:02, 
and -B*065:01. The Bw4 motif was necessary for Mamu-KIR3DL01 recognition, since 
substitutions in this region abrogated Mamu-KIR3DL01+ NK cell inhibition. However, the 
presence of a Bw4 motif was not sufficient for recognition, since another Bw4 molecule, Mamu-
B*017:01, failed to suppress the cytolytic activity of these NK cells. Replacement of three 
residues in Mamu-B*017:01, predicted to be KIR-contacts based on the 3-dimensional structure 
of the human KIR3DL1-HLA-Bw4 complex, with the corresponding residues at these positions 
for the other Mamu-Bw4 ligands restored Mamu-KIR3DL01+ NK cell inhibition. These results 
define the ligand specificity of one of the most polymorphic and commonly expressed KIRs in 
the rhesus macaque, and reveal similarities in Bw4 recognition by Mamu-KIR3DL01 and human 
KIR3DL1, despite the absence of an orthologous relationship between these two KIRs or 
conservation of surface residues predicted to interact with MHC class I ligands. 
	  27	  
2.3 - Introduction 
Natural killer (NK) cells are able to recognize and kill virus-infected cells and tumor cells 
without prior antigenic stimulation, and therefore constitute an important innate cellular defense 
against infectious diseases and cancers. NK cell responses in primates are regulated in part 
through interactions between two highly polymorphic molecules, the killer-cell Ig-like receptors 
(KIRs) on NK cells and their major histocompatibility complex (MHC) class I ligands on target 
cells. Depending on sequences in their transmembrane and cytoplasmic domains, KIRs can 
transduce either inhibitory or activating signals. In the case of inhibitory KIRs, NK cell 
activation is suppressed upon receptor engagement of MHC class I ligands on the surface of 
healthy cells. Thus, NK cells bearing inhibitory KIR may become activated upon disruption of 
ligand recognition, either as a consequence of MHC class I downregulation by viral infection 
(13, 68, 98, 192, 193), deletion of MHC class I genes during tumor progression (134), or MHC 
class I presentation of antagonistic peptides (157).  
Genetic evidence suggests that KIR and MHC class I polymorphisms play a significant 
role in determining the course of infection for several human pathogens, including hepatitis C 
virus (194), hepatitis B virus (195, 196), human papilloma virus (197, 198), herpes simplex virus 
(199), and human immunodeficiency virus (176, 177). However, studies addressing the 
functional implications of these observations have been limited by the lack of a suitable animal 
model. Mice and other rodents do not express KIRs, but instead use C-type lectin-like molecules 
encoded by the Ly49 genes as polymorphic NK cell receptors for MHC class I ligands (125). 
Moreover, KIRs appear to be evolving at a particularly rapid pace in primates (200-203). As a 
consequence, there is little conservation among the KIR genes of different species, and it is not 
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possible to predict the specificity of KIR-MHC class I interactions on the basis of sequence 
comparisons with human KIRs. 
The rhesus macaque is an important animal model for acquired immunodeficiency 
syndrome research (9), and for other viral diseases caused by Epstein-Barr virus (204), 
cytomegalovirus (205), and Kaposi’s sarcoma-associated herpesvirus (206). Immunogenetic 
characterization of this species has also contributed to our basic understanding of the co-
evolution of KIR and MHC class I genes. Rhesus macaques have duplicated Mamu-A and -B 
genes, which correspond to HLA-A and -B in humans (207, 208). However, they do not have a C 
locus, since HLA-C represents a duplication of an ancestral B gene that occurred after the 
divergence of apes and Old World monkeys (207, 208). There are as many as four Mamu-A 
genes and an undefined and variable number of Mamu-B genes on any given haplotype in the 
rhesus macaque (209, 210). In accordance with KIR and MHC class I co-evolution, macaques 
lack lineage III KIR genes, which encode KIR2DL/S specific for HLA-C (211, 212), and instead 
have an expanded repertoire of KIR3DL/S genes characterized by extensive polymorphism (203, 
211-214). Indeed, 19 distinct KIR3DL/S genes have been identified in rhesus macaques (213, 
215). 
The recognition of MHC class I molecules by human KIRs is primarily determined by 
sequences in the ligand α1 and α2 domains. All HLA-B molecules, and some HLA-A molecules, 
can be classified as either Bw4 or Bw6 allotypes on the basis of residues at positions 77-83 in the 
α1 domain (216). KIR3DL1 is the most polymorphic human KIR and recognizes diverse HLA 
class I ligands that share a Bw4 motif (141). The contribution of Bw4 residues to ligand 
recognition by KIR3DL1 was recently corroborated by a crystal structure of KIR3DL1*001 in 
complex with HLA-B*5701, which revealed multiple contacts between the D1 domain of 
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KIR3DL1*001 and Bw4 residues of HLA-B*5701 (152). This structure also revealed additional 
contacts between the D1 and D2 domains of KIR3DL1*001 and the α1 and α2 domains of HLA-
B*5701, indicating that the Bw4 motif is not the sole determinant of ligand recognition (152). 
Only a few MHC class I ligands have been defined for non-human primate KIRs. In the 
rhesus macaque, these include the identification of Mamu-A1*002 as a ligand for Mamu-
KIR3DL05 by binding and cellular assays (143, 144), with additional binding partners for 
Mamu-KIR3DL05, -3DLW03, -3DL11 and -3DS05 revealed by staining with soluble KIR-Fc 
fusion proteins (143). In the pig-tailed macaque, Mane-A1*082 and -A1*084 were also 
identified as ligands for KIR049-4 (217). However, the value of most of these interactions for 
studying NK cell responses in KIR- and MHC class I-defined animals remains limited due to the 
lack of reagents for staining specific KIR on primary macaque NK cells.  
Here we show that a monoclonal antibody (mAb) to human KIR2D molecules binds 
allotypes of Mamu-KIR3DL01 bearing an aspartic acid at position 233. We use this Ab to define 
the ligand specificity of Mamu-KIR3DL01, a commonly expressed and highly polymorphic KIR 
in the rhesus macaque. Our results reveal similarities in the recognition of Bw4 molecules by 
Mamu-KIR3DL01 and human KIR3DL1, despite the absence of an orthologous relationship 
between these two KIRs. These observations provide an important foundation for studying NK 
cell responses in KIR- and MHC class I-defined rhesus macaques and reveal an ancient origin for 
Bw4 specificity prior to the divergence of apes and Old World monkeys. 
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2.4 - Materials and Methods 
Ethics statement 
Indian origin rhesus macaques (Macaca mulatta) were used in this study. Housing and 
care of the animals at the New England Primate Research Center (NEPRC) were in accordance 
with standards of the Association for Assessment and Accreditation of Laboratory Animal Care 
and the Harvard Medical School Animal Care and Use Committee. Animal experiments were 
approved by the Harvard Medical Area Standing Committee on Animals and conducted 
according to the principles described in the Guide for the Care and Use of Laboratory Animals 
(218). 
 
Phenotyping of NKVFS1+ lymphocytes 
Unless otherwise noted, all antibodies are from BD Biosciences. PBMC were isolated by 
Ficoll-Paque (GE Healthcare) and stained with anti-CD3-V500 (clone SP34-2), anti-NKG2A-
Pacific Blue (clone Z199, in house conjugation), anti-CD4-FITC (clone L200), anti-HLA-DR-
TexasRed (clone Immu-357; Beckman Coulter), anti-CD20-PE-Cy5.5 (clone L27), anti-CD56-
PE-Cy7 (clone B159), anti-KIR2D-APC (clone NKVFS1; Miltenyi Biotec), anti-CD8-Alexa700 
(clone RPA-T8), anti-CD16-APC-Cy7 (clone 3G8), and anti-CD14-PE (clone MφP9) or anti-
NKG2D-PE (clone BAT221; Miltenyi Biotec) for 20 min at 25°C. Samples were washed and 
fixed in 2% paraformaldehyde PBS. At least 2 x 105 lymphocyte events were collected using an 
LSRII flow cytometer (BD Biosciences), and the data was analyzed using FlowJo 8.8.7 (Tree 
Star). 
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Electroporation of Jurkat cells with KIR-expression constructs 
Jurkat cells (107 cells) were electroporated (250 V, 950 µF) with 40 µg of plasmid DNA 
encoding hemagglutinin (HA)-tagged KIR in the pCGCG vector in 350 µL of RPMI 1640 
(Invitrogen) in a 0.4 cm cuvette using the GenePulser ShockPod system (Bio-Rad). Cells were 
rested for ten minutes, then cultured overnight in RPMI 1640 supplemented with 10% FBS 
(Invitrogen), HEPES, and glutamine (Invitrogen). Twenty-four hours later, cells were stained 
with anti-HA-PE (clone GG8-IF3.3; Miltenyi Biotec) and anti-KIR2D-APC for 20 min at 25°C. 
Samples were washed and fixed in 2% paraformaldehyde PBS. At least 3 x 105 events were 
collected using a FACSCalibur flow cytometer, and the data was analyzed, using FlowJo 8.8.7, 
after gating on GFP+ cells as the transfected subset.  
 
721.221 stable cell lines 
Rhesus macaque MHC class I cDNAs were cloned into pQCXIP or pQCXIN retroviral 
vectors (BD Clontech). These vector were packaged into VSV-G pseudotyped MLV-based 
particles by cotransfection with pVSV-G (BD Clontech) into GP2-293 cells (BD Clontech). 
Supernatant was collected from transfected GP2-293 cells two days post-transfection and 
concentrated by centrifugation in Ultracel 50k filter centrifuge tubes (Millipore). 721.221 cells 
were transduced by incubation with concentrated virus for 3 hours at 37˚C. Three days later, 
cells were placed under selection with 0.4 ug/mL puromycin (Invitrogen) or 500 ug/mL of G418 
(Calbiochem). Surface expression of transduced MHC class I molecules was verified by flow 
cytometry staining with a PE-conjugated pan-MHC class I-specific mAb (clone W6/32; 
DakoCytomation). 
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NK cell expansion and cell culture 
Peripheral blood mononuclear cells (PBMC; 5 x 106 cells) were cultured with 1 x 107 γ-
irradiated K562 Clone 9.mbIL21 cells (219) in a volume of 40 mL of RPMI 1640 (Invitrogen) 
supplemented with 10% FBS, glutamine, primocin (InvivoGen), and 50 U/mL IL-2 (AIDS 
Research and Reference Reagent Program). On days 3 and 5 after stimulation, cells were 
resuspended in fresh medium. The expanded NK cells were re-stimulated on day 7, and weekly 
thereafter with additional γ-irradiated K562 Clone 9.mbIL21 cells at a 1:1 ratio. From day 7 
onward, expanded cells were maintained at 4 x 105 cells/mL by resuspension in fresh medium 2-
3 times weekly.  
 
NK cell sorting 
T cells were depleted from expanded NK cell cultures by incubation with anti-CD3 Ab 
(clone 6G12) followed by immunomagnetic bead depletion with pan-mouse IgG Dynabeads 
(Dynal Biotech). Mamu-KIR3DL01+ and -KIR3DL01- subsets were separated by FACS using a 
pan-KIR2D-specific mAb (clone NKVFS1) that cross-reacts with a subset of Mamu-KIR3DL01 
allotypes. NK cells were stained with anti-CD3-Pacific Blue (clone SP34-2; BD Biosciences), 
anti-NKG2A-APC (clone Z199; Beckman Coulter), and anti-KIR2D-FITC (clone NKVFS1; 
AbD Serotec) or anti-NKG2A-Pacific Blue, anti-CD3-FITC (clone SP34; BD Biosciences), and 
NKVFS1-APC. NKVFS1+CD3-NKG2A+ and NKVFS1-CD3-NKG2A+ subsets were sorted using 
a FACSAria (BD Biosciences). These sorted NK cells subsets were maintained as described 
above by re-stimulation with γ-irradiated K562 Clone 9.mbIL21 cells. 
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CD107a degranulation assay 
PBMC (1x106 cells) were stimulated for 6 hours with parental 721.221 cells, or with 
721.221 cells that constitutively express rhesus macaque MHC class I molecules, at a 5:1 ratio in 
the presence of anti-CD107a-PE-Cy5 (clone H4A3; BD Biosciences), GolgiStop, and GolgiPlug 
(BD Biosciences). The cells were then stained with anti-CD3-FITC, anti-NKG2A-PE, and 
NKVFS1-APC for 20 min at 25°C. Samples were washed and fixed in 2% paraformaldehyde 
PBS. At least 2 x 105 lymphocyte events were collected using a FACSCalibur flow cytometer, 
and the data was analyzed using FlowJo 8.8.7. 
 
Calcein acetoxymethyl ester cytotoxicity assay 
Parental 721.221 cells or 721.221 cells expressing rhesus macaque MHC class I 
molecules were stained with calcein acetoxymethyl ester (CAM; Invitrogen) at a 1:100 dilution 
for 1 hr at 37°C. Cells were washed and then incubated with KIR3DL01+ or KIR3DL01- NK 
cells for 4 hours at E:T ratios between 0.5:1 and 10:1. The release of CAM into the supernatant 
was measured using a fluorescent plate reader (excitation 485 nm, absorption 530 nm). Percent 
specific lysis was calculated as (test release – spontaneous release) / (maximum release – 
spontaneous release).  
 
KIR sequencing 
Total RNA was isolated from PBMC using an AllPrep DNA/RNA mini kit (Qiagen). 
cDNA was synthesized using a Superscript III cDNA first strand synthesis system using 
Oligo(dT) primers (Invitrogen). cDNA was PCR amplified using Phusion high fidelity DNA 
polymerase (New England Biolabs) with two primer sets for each animal. One primer set 
	  34	  
produced a 669bp amplicon containing Roche/454 titanium adaptors and multiplex identifier tags 
attached to the following sequence-specific primer sequences: KIR-405-F 5’-
AGGTCCCCTGGTGAAATCAG-3’ and KIR-1004-R 5’-CTTGGTTCAGTGGGTGAAGG-3’. 
The PCR conditions for this amplicon were previously published (220). These amplicons were 
purified using Agencourt AMPure XP size selection beads (Beckman Coulter), quantitated using 
picogreen dye (Qubit), and pooled at equimolar ratios. The pool was amplified using emulsion 
PCR, the emulsions broken, and beads containing DNA with both adaptors were enriched and 
sequenced on a Roche/454 GS Junior using Titanium technology and standard protocols 
provided with the sequencing kits. 
The other primer set amplified the full-length KIR coding sequence with a variety of 
expected sizes up to 1500bp, depending upon the KIR alleles within the animal, with the 
following sequence-specific primer sequences: KIR5’UTR.3 5’-CAGCACCATGTCGCTCAT-
3’ and KIR3’UTR-C 5’-GGGGTCAAGTGAAGTGGAGA-3’. The full-length KIR alleles were 
amplified with Phusion high fidelity DNA polymerase (New England Biolabs) under the 
following conditions: 98°C for 30 s, 28 cycles of 98°C for 5 s, 60°C for 10 s, and 72°C for 30 s, 
followed by a 5 min extension at 72°C. These amplicons were purified using AMPure XP beads 
and fragmented using Nextera XT tagmentation (Illumina), which leaves a unique Illumina-
specific index identifier associated with each sample. Fragment size was determined by 
bioanalysis (Agilent-high sensitivity chip) and concentration determined by picogreen dye. 
Normalized samples were pooled together, denatured, and run on an Illumina MiSeq system 
using a 500 cycle MiSeq cartridge.  
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KIR genotype analysis 
The Roche/454 sequences were trimmed for quality (error probability limit of 0.01) and 
then reads >300bp were de novo assembled with 100% minimum overlap identity and 0% 
mismatches per read using Geneious version 6.1 (221, 222). Consensus sequences generated 
from the assembly were trimmed with an error probability limit of 0.0001, 0 low quality bases, 0 
maximum ambiguities and trimmed for primer sequences. These sequences were again de novo 
assembled at 99% minimum overlap identity and 1% maximum mismatches per read and 
consensus sequences were trimmed with the parameters above. These consensus sequences 
representing each allele within an animal were used as a backbone against which the MiSeq 
250bp paired-end reads were mapped over multiple iterations using Geneious version 6.1 
software. To begin, MiSeq generated paired-end sequences were set to pair the ends and trimmed 
for a quality of 0.01. Sequences >150bp were trimmed for primers and sequences >100bp were 
subjected to multiple iterations of assembly. The first iteration consisted of custom assembling 
the paired and trimmed MiSeq reads against a list of consensus sequences (backbones) 
representing the alleles found in each animal by the Roche/454 analysis with a minimum overlap 
identity of 100% over a minimum overlap of 95bp, 0% mismatches, and mapping best matches 
to none to avoid sequences mapping to more than one backbone. These Roche/454-based 
consensus sequences were elongated by the paired ends during this assembly and were then 
trimmed with an error probability limit of 0.0001. The elongated and trimmed consensus 
sequences generated from both the Roche/454 and MiSeq sequences were used as the backbone 
in place of the Roche/454 sequences for the next iteration of mapping the paired MiSeq 
sequences against. This iterative mapping continued until the KIR alleles no longer extended. 
Many alleles were extended from the 669 bp Roche/454 read length to full-length including start 
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and stop codons for each allele found within an animal. The final sequence assemblies were then 
blasted against a database of all KIRs published in Genbank to determine the identity of the KIR 
alleles for each animal. Allele designations were assigned by the Immuno Polymorphism 
Database (223). 
 
Phylogenetic analysis of rhesus and human KIRs 
Full-length amino acid sequences were aligned using MacVector 12.0.6 (MacVector). 
Phylogenetic trees were generated by the Neighbor-Joining method using MEGA 5.2 (224). The 
bootstrap method with 500 replicates was used with pairwise deletion and the Poisson correction 
was used in computing evolutionary distances.  
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2.5 - Results 
A monoclonal Ab to human KIR2D stains rhesus macaque NK cells and CD8+ T cells 
We previously observed that a mAb to human KIR2D (clone NKVFS1) stained a 
peripheral blood lymphocyte population in some rhesus macaques (144). Further characterization 
of this population revealed that the majority of these cells express antigens typical of NK cells, 
including CD8, CD16, NKG2D, and NKG2A (Supplemental Figure 2.1A). The NKVFS1+ 
population consisted of NK cells (CD3-CD8+NKG2A+) and, to a lesser extent, CD8+ T cells 
(CD3+CD8+NKG2A-) (Supplemental Figure 2.1B). NKVFS1+ cells were observed in each of the 
four NK cell subsets defined by CD16 and CD56 expression (Supplemental Figure 2.1C). These 
results, and the similar staining pattern observed for Mamu-KIR3DL05 on peripheral blood 
lymphocytes (144), suggest that NKVFS1 cross-reacts with a rhesus macaque KIR. 
 
NKVFS1 binds to Mamu-KIR3DL01 allotypes with an aspartic acid residue at position 233 of 
the D2 domain 
To identify the rhesus macaque KIR bound by NKVFS1, each of the KIR alleles cloned 
from an NKVFS1+ animal were expressed from a construct with an HA tag at the N terminus of 
the D0 domain (144). Jurkat cells were transfected with these constructs and stained with 
NKVFS1 and a HA-specific mAb. For cells expressing Mamu-KIR3DL01*001, KIR expression 
correlated with NKVFS1 staining (Figure 2.1). In contrast, cells expressing another Mamu-
KIR3DL01 allele from this animal, Mamu-KIR3DL01*002, did not stain with NKVFS1. Since 
the Ig-like domains of these molecules differ by only eight amino acids (Figure 2.2A), reciprocal 
substitutions at each of these positions were tested to define the epitope bound by NKVFS1. An 
aspartic acid to histidine change at position 233 (D233H) of Mamu-KIR3DL01*001 abrogated 
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staining by NKVFS1, whereas substitutions at positions 71, 93/96/98, 104, 173, or 181 did not 
affect NKVFS1 staining (Figure 2.2B). Conversely, a histidine to aspartic acid substitution at 
position 233 (H233D) in Mamu-KIR3DL01*002 resulted in staining with NKVFS1. These 
results indicate that residue 233 of Mamu-KIR3DL01*001, predicted to be a surface residue in 
the D2 domain (152), differentiates allotypes of Mamu-KIR3DL01 that bind NKVFS1 from 
those that do not. This distinction was confirmed by positive NKVFS1 staining of cells 
expressing Mamu-KIR3DL01*014, *017, or *020 (Figure 2.2C), all of which have an aspartic 
acid at position 233.  
 
 
Figure 2.1. NKVFS1 stains Mamu-KIR3DL01*001. Jurkat cells were electroporated with HA-
tagged KIR expression constructs that co-express GFP and were stained with the NKVFS1 Ab 
and an HA-specific mAb. Samples were gated on GFP+ cells and analyzed for NKVFS1 versus 
anti-HA staining. Data shown is representative of results obtained in three independent 
experiments. 
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Figure 2.2. Residue 233D is essential for NKVFS1 binding to Mamu-KIR3DL01*001. (A) An 
amino acid alignment shows residues that differ between Mamu-KIR3DL01*001 and -
KIR3DL01*002 in D0, D1, and D2. (B) Jurkat cells were electroporated with constructs 
expressing HA-tagged KIR with reciprocal substitutions at positions that differ between Mamu-
KIR3DL01*001 and -KIR3DL01*002, or (C) constructs expressing five different Mamu-
KIR3DL01 alleles. Staining of GFP+ cells for HA and NKVFS1 is shown. Data shown is 
representative of results obtained in three independent experiments. 
 
Table 2.1. Mamu-KIR3DL01 alleles expressed by the rhesus macaques in this study.	  
Animal Mamu-KIR3DL01 allele Residues 230-236 
*001 TSFDMYH 1 *016 TSFDMYH 
2 *019 TSFDMYH 
3 *019 TSFDMYH 
4 *015 TSFDMYH 
5 *019 TSFDMYH 
The residue indicated in bold is the aspartic acid at position 233 of Mamu-KIR3DL01 that is 
necessary for binding by the mAb NKVFS1. 
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Identification of MHC class I ligands for Mamu-KIR3DL01 
Having identified Mamu-KIR3DL01 D233 allotypes as the surface antigen bound by 
NKVFS1, we next sought to define the MHC class I ligands recognized by this KIR. The 
NKVFS1 Ab was used to identify additional rhesus macaques expressing Mamu-KIR3DL01 
D233, and the presence of alleles coding for this KIR was confirmed by deep sequencing (Table 
2.1). PBMC from four Mamu-KIR3DL01+ macaques were stimulated with MHC class I-
deficient 721.221 cells (225), or 721.221 cells that constitutively express rhesus macaque MHC 
class I molecules, and stained for CD107a as a degranulation marker. The frequency of NK cells 
with surface CD107a was compared between Mamu-KIR3DL01+ (NKVFS1+) and -KIR3DL01- 
subsets from the same animal. Whereas a similar percentage of Mamu-KIR3DL01+ and -
KIR3DL01- NK cells degranulated in response to parental 721.221 cells and 721.221 cells 
expressing Mamu-A1*001:01, -B*017:01, -B*022:01 and -B*056:01, CD107a upregulation by 
the Mamu-KIR3DL01+ subset was selectively suppressed by incubation with 721.221 cells 
expressing Mamu-B*007:01-, -B*041:01, -B*058:02, and -B*065:01 (Figure 2.3A). This result 
was reproducible using NK cells from four unrelated animals (Figure 2.3B).  
To corroborate these results, NK cell recognition of 721.221 cells expressing rhesus 
macaque MHC class I molecules was evaluated in cytotoxicity assays.  Primary NK cells were 
expanded by stimulation with γ-irradiated K562 Clone 9.mbIL21 cells, which express CD64 
(FcγRI), CD86 (B7-2), CD137L (4-1BBL), truncated CD19, and membrane-bound IL-21 (226). 
Expanded NK cells were sorted into Mamu-KIR3DL01+ and -KIR3DL01- subsets by staining 
with the NKVFS1 Ab and were used as effector cells in cytotoxicity assays with 721.221 cells 
expressing rhesus MHC class I molecules as target cells. The 721.221 target cells were labeled 
with calcein acetomethyl ester (CAM), a cell-permeable dye that is converted to fluorescent 
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calcein by cellular esterases (227, 228), and incubated with NK cells for four hours. The release 
of CAM into the supernatant was measured using a fluorescent plate reader to calculate the 
percent specific lysis.  The Mamu-KIR3DL01- NK cells lysed all of the 721.221 cell lines 
regardless of MHC class I expression. However, the cytolytic activity of the Mamu-KIR3DL01+ 
NK cells was inhibited by certain MHC class I molecules. Whereas 721.221 cells expressing 
Mamu-A1*001:01, -B*017:01, or -B*056:01 were lysed as efficiently as parental 721.221 cells 
by Mamu-KIR3DL01+ NK cells, target cells expressing Mamu-B*007:01, -B*041:01, -
B*058:02, and -B*065:01 inhibited lysis by Mamu-KIR3DL01+ NK cells (Figure 2.3C). The 
intermediate inhibition shown with target cells expressing Mamu-B*022:01 was only observed 
with NK cells from two of three animals. In contrast, the inhibition of Mamu-KIR3DL01+ NK 
cells by Mamu-B*007:01, -B*041:01, -B*058:02, and -B*065:01 was reproducible with NK 
cells from three animals (Figure 2.3D). These data corroborate results obtained by CD107a 
staining and define these four molecules as ligands for Mamu-KIR3DL01. 
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Figure 2.3. Mamu-B*007:01, -B*041:01, -B*058:02, and -B*065:01 are ligands for Mamu-
KIR3DL01. (A) PBMC were stimulated overnight with parental 721.221 cells, or 721.221 cells 
expressing the indicated MHC class I molecules at a 5:1 ratio in the presence of a mAb to 
CD107a, and stained with NKVFS1 and antibodies to CD3 and CD8. After gating on CD3-CD8+ 
lymphocytes, the upregulation of CD107a on NKVFS1+ versus NKVFS1- NK cell subsets was 
assessed. (B) The frequency of CD107a upregulation for Mamu-KIR3DL01+ and -KIR3DL01- 
populations is summarized for four different animals where error bars indicate + 1 SD. Asterisks 
indicate a significant difference (*p<0.05, **p<0.01, ***p<0.005 by two-way ANOVA with 
Dunnett’s test) between Mamu-KIR3DL01+ and -KIR3DL01– populations coincubated with a 
given 721.221 cell line. (C) Mamu-KIR3DL01+ and -KIR3DL01- NK cells from the same animal 
were coincubated with parental 721.221 cells or 721.221 cells expressing the indicated rhesus 
macaque MHC class I molecules at the indicated effector:target (E:T) ratios. Killing of target 
cells was evaluated by release of CAM from target cells into the culture supernatant. % Specific 
Lysis is defined as (test release – spontaneous release) / (maximum release – spontaneous 
release). Results are representative of those obtained with expanded cells from three different 
animals and the compiled results for Mamu-KIR3DL01+ NK cells from these animals are 
presented in (D). Error bars indicate + 1 SD. Asterisks indicate a significant difference (*p<0.05, 
****p<0.001 by two-way ANOVA with Dunnett’s test) between coincubation with 721.221 
parental cells and coincubation with the indicated cell line at all E:T ratios shown. 
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Residues in the Bw4 epitope contribute to recognition by Mamu-KIR3DL01 
Since the rhesus macaque MHC class I molecules identified as ligands for Mamu-
KIR3DL01 all have a Bw4 motif at positions 77-83 in the α1 domain (216), substitutions were 
introduced into this sequence to determine if the Bw4 motif contributes to recognition by Mamu-
KIR3DL01. Mamu-B*065:01 residues at positions that differ between Bw4 and Bw6 motifs (77, 
80, 81, 82, and 83) were exchanged, separately and in combination, with the corresponding Bw6 
residues at these positions. 721.221 cells expressing these Mamu-B*065:01 mutants were tested 
for recognition by sorted primary Mamu-KIR3DL01+ and -KIR3DL01- NK cells from the same 
animal in CAM cytotoxicity assays. Whereas none of the MHC class I mutants inhibited the 
cytolytic activity of the Mamu-KIR3DL01- NK cells, 721.221 cells expressing Mamu-B*065 
with an alanine to leucine substitution at position 81 (A81L) or a leucine to arginine substitution 
at position 82 (L82R) inhibited the cytolytic activity of Mamu-KIR3DL01+ NK cells to a similar 
extent as cells expressing wild-type Mamu-B*065 (Figure 2.4A). However, 721.221 cells 
expressing Mamu-B*065 with an asparagine to serine substitution at position 77 (N77S), a 
threonine to asparagine substitution at position 80 (T80N), an arginine to glycine substitution at 
position 83 (R83G), or Bw6 residues at each of the five positions (Mamu-B*065-Bw6), were 
susceptible to lysis by Mamu-KIR3DL01+ NK cells (Figure 2.4A). The susceptibility of cell 
lines expressing Mamu-B*065-N77S, -T80N, -R83G, or -Bw6 to lysis by Mamu-KIR3DL01+ 
NK cells was reproducible using primary NK cells isolated from three unrelated animals (Figure 
2.4B). Thus, residues 77, 80, and 83 within the Bw4 epitope contribute to ligand recognition by 
Mamu-KIR3DL01.  
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Figure 2.4. Mamu-KIR3DL01 recognition of Mamu-B*065 is dependent upon Bw4 residues 
N77, T80, and R83. Mutations were introduced into the Bw4 region of Mamu-B*065:01 to make 
it Bw6-like at positions which vary between Bw4 and Bw6. (A) Mamu-KIR3DL01+ and -
KIR3DL01- NK cells from the same animal were coincubated with parental 721.221 cells or 
721.221 cells expressing the indicated Mamu-B*065:01 mutants at the indicated E:T ratios. 
Killing of target cells was evaluated by release of CAM from target cells into the culture 
supernatant. Results are representative of expanded NK cells from three different animals, and 
the compiled results for Mamu-KIR3DL01+ NK cells from these animals are presented in (B) 
wherein error bars indicate + 1 SD. Asterisks indicate a significant difference (*p<0.05, 
****p<0.001 by two-way ANOVA with Dunnett’s test) between coincubation with 721.221-
Mamu-B*065 cells and coincubation with 721.221 cells expressing a given Mamu-B*065 mutant 
at all E:T ratios shown. 
 
Additional MHC class I residues necessary for recognition by Mamu-KIR3DL01 
Although Mamu-B*017:01 is identical to Mamu-B*007:01 and -B*065:01 at positions 
77-83, Mamu-B*017:01 did not suppress the activation of Mamu-KIR3DL01+ NK cells, 
indicating that the presence of a Bw4 motif in the α1 domain is not sufficient for recognition by 
Mamu-KIR3DL01. To identify additional residues necessary for this interaction, reciprocal 
substitutions between Mamu-B*017:01 and -B*065:01 were introduced at polymorphic sites 
predicted to be contact residues based on the KIR3DL1-HLA-B*57 crystal structure (Figure 
2.5A) (152). 721.221 cells expressing these MHC class I mutants were tested for recognition in a 
CAM cytotoxicity assay with sorted Mamu-KIR3DL01+ and -KIR3DL01- NK cells from the 
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same animal. None of the MHC class I mutants inhibited the cytolytic activity of the Mamu-
KIR3DL01- NK cells. Whereas 721.221 cells expressing wild-type Mamu-B*065:01 suppressed 
killing by Mamu-KIR3DL01+ NK cells, substitutions in Mamu-B*065 at positions 76 (G76E), 
142 (F142N), or 149 (A149G) abrogated this inhibition (Figure 2.5B). Consistent with a role for 
these residues in recognition by Mamu-KIR3DL01, a combination of all three reciprocal 
substitutions was necessary to efficiently inhibit the cytolytic activity of Mamu-KIR3DL01+ NK 
cells in the context of Mamu-B*017:01 (Figure 2.5B). These results were reproducible with 
Mamu-KIR3DL01+ NK cells from three different animals (Figure 2.5C). Therefore, in 
accordance with the three-dimensional structure of human KIR3DL1 in complex with HLA-
B*57, additional residues in the α1 and α2 domains, including G76, F142, and A149, contribute 
to ligand recognition by Mamu-KIR3DL01.  
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Figure 2.5. Residues G76, F142, and A149 are determinants of recognition by Mamu-
KIR3DL01. (A) An amino acid alignment of the MHC class I α1 and α2 domains of Mamu-
B*065:01, -B*007:01, and -B*017:01 with the predicted KIR contact residues highlighted based 
on the HLA-B*57:KIR3DL1*001 crystal structure (152). Reciprocal substitutions were 
introduced into Mamu-B*065:01 and -B*017:01 at each of the positions indicated with asterisks 
that are the same for Mamu-B*065:01 and -B*007:01, but differ for Mamu-B*017:01. (B) 
Mamu-KIR3DL01+ and -KIR3DL01- NK cells from the same animal were coincubated with 
parental 721.221 cells or 721.221 cells expressing the indicated rhesus macaque MHC class I 
mutants at E:T ratios ranging from 10 to 0.625. Cytotoxicity was measured by the release of 
CAM from target cells into the culture supernatant. Results are representative of those obtained 
with expanded cells from three different animals, and the compiled results for Mamu-
KIR3DL01+ NK cells from these animals are presented in (C), wherein error bars indicate + 1 
SD. Asterisks indicate a significant difference (*p<0.05, **p<0.01, ****p<0.001 by two-way 
ANOVA with Dunnett’s test) between coincubation with 721.221-Mamu-B*065:01 or -
B*017:01 cells and coincubation with 721.221 cells expressing a given Mamu-B*065:01 or -
B*017:01 mutant at all E:T ratios shown. 
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Comparison of rhesus macaque and human Bw4 ligands 
Many of the residues required for Mamu-KIR3DL01 recognition of rhesus macaque Bw4 
molecules are also contact residues in the human KIR3DL1:HLA-B*57 crystal structure (152). 
An amino acid alignment of HLA-B*57 and the seven Mamu-B molecules investigated in this 
study demonstrates that 13 of the 17 predicted KIR contact residues are conserved among these 
molecules (Figure 2.6A). Notably, residues 76 and 142 differ between HLA-B*57 and the 
Mamu-KIR3DL01 ligands, despite their importance for KIR recognition in both species. These 
residues, along with residue 149, are also polymorphic among the Mamu-B molecules studied. 
Whereas the four molecules identified as ligands for Mamu-KIR3DL01 have residues G76, 
F142, and A149, the non-ligands (Mamu-B*017:01, -B*022:01, and -B*056:01) have an 
asparagine at position 142 (N142), with Mamu-B*017:01 also differing at the two other 
positions. These three residues, and the Bw4 motif residues 77, 80, and 83, are located at surface 
exposed positions near the C-terminus of the α1-domain and the N-terminus of the α2-domain 
(Figure 2.6B), partially overlapping the footprint of KIR3DL1 bound to HLA-B*57 (152).  
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Figure 2.6. KIR contact residues of rhesus macaque Bw4 molecules. (A) An amino acid 
alignment of the MHC class I α1 and α2 domains of HLA-B*5701 and Mamu-B*065:01, -
B*007:01, -B*017:01, -B*022:01, B*041:01, B*056:01, and B*058:02 with the predicted KIR 
contact residues shaded based on the HLA-B*57:KIR3DL1*001 crystal structure (152).  (B) 
Crystal structure of HLA-B*57 (yellow) and bound peptide (cyan). Highlighted in red are 
positions important for recognition by Mamu-KIR3DL01 identified in this study: residues 76, 77, 
80, 83, 142, and 149. 
 
A 
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Mamu-KIR3DL01 is phylogenetically distinct from human KIR3DL1 
Despite their shared specificity for Bw4 ligands and a coincidental similarity in 
nomenclature, Mamu-KIR3DL01 and human KIR3DL1 are not orthologous gene products. This 
is illustrated by phylogenetic comparisons of the predicted amino acid sequences for human and 
rhesus macaque KIRs. In contrast to Mamu-KIR2DL04 and human KIR2DL4, which cluster 
together as the most conserved KIR between humans and rhesus macaques (203), Mamu-
KIR3DL01 and human KIR3DL1 are separated by deep branch lengths and are more similar to 
other KIRs of their respective species than they are to each other (Figure 2.7A). A nearly 
identical tree was obtained from an analysis that was restricted to the D1 and D2 domains, 
indicating that the shared specificity of Mamu-KIR3DL01 and human KIR3DL1 for Bw4 
molecules is not the result of greater similarity in their ligand-binding domains (data not shown).  
Indeed, only 7 of the 16 residues in the D1 and D2 domains of KIR3DL1 that participate in 
interactions with HLA-B*57 match residues in Mamu-KIR3DL01 (Figure 2.8B). Interestingly, 
most of these conserved residues are in the D2 domain. Whereas 7 of the 11 HLA-contact 
residues of KIR3DL1 are conserved in the D2 domain of Mamu-KIR3DL01, none of 5 contacts 
match D1 domain residues of Mamu-KIR3DL01 (Figure 2.7B-C). Thus, the specificity of 
Mamu-KIR3DL01 for Bw4 ligands could not have been predicted based on sequence similarity 
with human KIR3DL1.   
 
Figure 2.7. Phylogenetic analysis of human and rhesus macaque KIRs. (A) Midpoint-rooted 
phylogenetic tree generated from full-length amino acid sequences using Neighbor-Joining (NJ) 
method. Bootstraps were calculated with 500 iterations. (B) An amino acid alignment of the D0, 
D1, and D2 domains of human KIR3DL1 and allotypes of Mamu-KIR3DL01 with the predicted 
MHC ligand contact residues shaded based on the HLA-B*57:KIR3DL1*001 crystal structure 
(152). (C) Crystal structure of human KIR3DL1 with HLA-B*57 contact residues highlighted. 
Residues highlighted in red are conserved between KIR3DL1 and Mamu-KIR3DL01*001, 
whereas residues highlighted in yellow differ between the two KIRs.  
 
	  50	  
Figure 2.7 (Continued). 
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2.6 - Discussion 
The identification of MHC class I ligands for rhesus macaque KIRs is important for 
studying NK cell responses in this non-human primate model for AIDS and other infectious 
diseases. KIRs are of particular interest in the context of viruses due to genetic associations 
between KIR and MHC class I alleles and the ability to control certain viral infections, including 
HIV (176, 177). In this study, we identified a mAb that binds selectively to D233 allotypes of 
Mamu-KIR3DL01. Using this mAb to distinguish KIR3DL01+ NK cells, we identified Mamu-
B*007:01, -B*041:01, -B*058:02, and -B*065:01 as ligands for Mamu-KIR3DL01. We also 
defined residues in the α1 and α2 domains of these molecules that are essential for recognition by 
Mamu-KIR3DL01, facilitating the prediction of additional ligands for this KIR. These results 
reveal similarities in the recognition of Bw4 ligands by rhesus macaque KIR3DL01 and human 
KIR3DL1, despite differences in the MHC class I contact residues of these receptors and the 
considerable divergence of KIR and MHC class I genes since these species last shared a common 
ancestor.  
Mamu-B*007:01, -B*041:01, -B*058:02, and -B*065:01 are the first B molecules to be 
identified as KIR ligands in the rhesus macaque. As products of the extensively duplicated and 
highly polymorphic Mamu-B genes, the diversity of these molecules reflects the diversity of 
Mamu-KIR3DL01, which is the most polymorphic of the rhesus macaque KIRs (214). Mamu-
KIR3DL01 is also one of the most commonly expressed rhesus macaque KIRs [expressed by 
approximately 85-95% of Indian-origin animals (213-215, 220)], and is thus likely to play a 
significant role in regulating NK cell responses in a majority of animals. Therefore, the 
identification of MHC class I ligands for Mamu-KIR3DL01 is especially important for 
investigating the role of NK cells in vaccine and pathogenesis studies in rhesus macaques.  
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The Bw4 ligands of Mamu-KIR3DL01 and human KIR3DL1 share a number of features 
necessary for KIR recognition. Corresponding to the importance of arginine at position 83 for 
HLA-Bw4 recognition by human KIR3DL1 (152, 229), this residue is also critical for Bw4 
recognition by Mamu-KIR3DL01. Likewise, just as threonine or isoleucine at position 80 
contributes to interactions with human KIR3DL1 (152), a threonine at this position is important 
for Bw4 recognition by Mamu-KIR3DL01. Similar amino acid positions outside of the Bw4 
motif are also important for ligand recognition by these two KIRs. Replacement of amino acids 
76, 142, or 149 of Mamu-B*065:01 with the corresponding residues from Mamu-B*017:01 
impaired recognition by Mamu-KIR3DL01. Conversely, replacement of these three residues in 
Mamu-B*017:01 with the corresponding residues of the Mamu-Bw4 ligands conferred an 
interaction with Mamu-KIR3DL01. These results illustrate the similarity in Bw4 recognition by 
KIR3DL1 and Mamu-KIR3DL01, since these positions are also HLA-contact sites for KIR3DL1 
(152).  
However, there are also differences in the MHC class I residues required for recognition 
by Mamu-KIR3DL01 and human KIR3DL1. Whereas KIR3DL1 is dependent on leucine at 
position 82 (229), Mamu-KIR3DL01 recognizes ligands with leucine or arginine at this position 
equally well. Moreover, although position 77 is not a contact residue for KIR3DL1 (152), and 
substitutions at this position do not affect KIR3DL1 interactions with HLA-B*51:01 or -B*15:13 
(229), position 77 is essential for Bw4 recognition by Mamu-KIR3DL01. An asparagine-to-
serine substitution at this position in Mamu-B*065 abrogates its ability to inhibit Mamu-
KIR3DL01+ NK cells. Thus, Mamu-KIR3DL01 and human KIR3DL1 have overlapping, but 
distinct, specificities for their respective ligands.  
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 Although KIR recognition of Bw4 ligands has been maintained since humans and 
macaques last shared a common ancestor, the KIRs conferring this specificity have not. Fewer 
than half of the HLA-B*57 contact residues of KIR3DL1 are conserved with Mamu-KIR3DL01. 
Most of the differences between these receptors are in the D0 and D1 domains, which together 
retain only 2 of 10 MHC class I-contacts. In contrast, 7 of 11 MHC class I-contacts are retained 
in the D2 domain. Greater conservation of the D2 domain may reflect greater evolutionary 
constraint to preserve core MHC class I binding interactions, while allowing the D0 and D1 
domains more freedom to fine tune ligand specificity. This possibility is consistent with 
structural data revealing greater complementarity in shape and charge of residues at the D2 
interface (152), and the observation that polymorphisms in the D0 and D1 domains can affect the 
avidity and peptide-specificity of MHC class I interactions (144). 
The cross-reactivity of the anti-human KIR2D mAb NKVFS1 with D233 allotypes of 
Mamu-KIR3DL01, which comprise 20 of the 27 defined Mamu-KIR3DL01 allotypes (223), 
effectively doubles the number of KIR-defined NK cell subsets that can be studied in the rhesus 
macaque. Although several mAbs to rhesus macaque KIRs were recently described, only one 
was specific for a single KIR (230). Coincidentally, this mAb bound to Mamu-KIR3DL05 (230), 
which can also be stained with Mamu-A1*002 tetramers (144). The availability of reagents for 
differentiating NK cells expressing specific KIRs is essential for dissecting the role of KIRs in 
primary NK cell activation in vitro, and for monitoring longitudinal changes of specific NK cell 
subsets in vivo. NKVFS1 will therefore be especially useful for monitoring phenotypic and 
functional changes in Mamu-KIR3DL01 D233+ NK cells after experimental infection of rhesus 
macaques with SIV and other viral pathogens.  
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In summary, the present study identifies Mamu-B*007:01, -B*041:01, -B*058:02, and -
B*065:01 as ligands for Mamu-KIR3DL01. Further characterization of the determinants of 
ligand recognition revealed that this KIR has a similar specificity for Bw4 molecules as human 
KIR3DL1. As one of the most common and most polymorphic KIRs in the rhesus macaque, 
identification of the MHC class I molecules recognized by Mamu-KIR3DL01 provides an 
important foundation for studying NK cell responses in this non-human primate model. These 
observations also suggest that, despite the divergence of KIR and MHC class I genes (231), KIR 
specificity for Bw4 ligands has been maintained since rhesus macaques and humans last shared a 
common ancestor approximately 25 million years ago (232). 
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Chapter 3 
Modulation of Natural Killer Cell Activation by Simian 
Immunodeficiency Virus Peptides 
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3.2 - Abstract 
Natural killer cells recognize and kill virus-infected cells without prior antigenic 
stimulation, and thus provide an important innate defense against infection. NK cell responses in 
primates are regulated in part through interactions between two highly polymorphic molecules, 
the killer cell immunoglobulin-like receptors (KIRs) on NK cells and their MHC class I ligands 
on target cells. NK cells bearing inhibitory KIRs become activated upon disruption of MHC 
class I recognition. We previously reported that the binding of a common MHC class I molecule 
in the rhesus macaque, Mamu-A1*002, to the inhibitory receptor Mamu-KIR3DL05 is stabilized 
by certain SIV peptides, but not by others. In the present study, we used a Mamu-A1*002-
expressing, TAP-inhibited cell line and primary Mamu-KIR3DL05+ NK cells to screen SIV 
peptides in cytotoxicity assays for the ability to modulate NK cell activation. Twenty-eight of 75 
SIV peptides that bind to Mamu-A1*002 suppressed the cytolytic activity of Mamu-KIR3DL05+ 
NK cells, including three immunodominant CD8+ T cell epitopes previously shown to bind 
Mamu-A1*002. An analysis of peptide variants revealed that substitutions at positions 6, 7 or 8 
could change an inhibitory peptide into a non-inhibitory peptide, and vice versa, without altering 
the ability to bind to Mamu-A1*002. In competition assays with mixtures of inhibitory and non-
inhibitory peptides, low concentrations of inhibitory peptides dominated to suppress NK cell 
activation. These results demonstrate that viral peptides can modulate NK cell activation through 
KIR-MHC class I interactions, and are consistent with the hypothesis that immunodeficiency 
viruses may acquire changes in epitopes that increase the avidity of MHC class I ligands for 
inhibitory KIRs to suppress the activation of specific NK cell subsets. 
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3.3 - Introduction 
Natural killer (NK) cells are an important early defense against viral infection and 
cancers because they can recognize and kill infected or malignant cells without prior antigenic 
stimulation. NK cell responses in primates are regulated by signals received from cell surface 
receptors, including activating and inhibitory killer-cell immunoglobulin-like receptors (KIRs). 
Inhibitory KIR recognition of self-MHC class I molecules on the surface of healthy cells 
prevents NK cell activation. The disruption of interactions between inhibitory KIRs and their 
MHC class I ligands, as a result of MHC class I downregulation or deletion of MHC class I 
genes, can result in NK cell killing of virus-infected (13, 68, 98, 192, 193) and tumor cells (134), 
respectively. 
Crystal structures of KIRs in complex with ligand have revealed that although KIR 
binding to ligands is largely driven by residues in the α1 and α2 domains of the MHC class I 
molecule, contacts also exist between KIR and the MHC class I-bound peptide (145, 150-152). 
In fact, ligand recognition by inhibitory KIRs can be altered by the presented peptide (142, 146, 
156, 157, 160, 233-236). Loss of inhibition resulting from peptides that alter the interaction 
between an inhibitory KIR and its MHC class I ligand can therefore lead to NK cell killing (157). 
This peptide-dependent NK cell regulation is of particular interest in viral infection, during 
which the peptide repertoire presented by infected cells changes dramatically (158, 159) and may 
affect binding of inhibitory KIRs to MHC class I ligands.   
The importance of KIR-MHC class I interactions in viral infections has been suggested 
by the genetic association between KIR and MHC class I polymorphisms and the outcome of 
many viral infections, including hepatitis C virus (194), hepatitis B virus (195, 196), human 
papilloma virus (197, 198), HSV (199), and HIV (176, 177, 237). Furthermore, several HIV 
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polymorphisms have been detected that are associated with the expression of a specific KIR, 
suggesting selection by KIR-mediated immune pressure (188). HIV polymorphisms associated 
with KIR2DL2 expression result in increased binding of this inhibitory KIR to infected cells and 
a decrease in the ability of NK cells from KIR2DL2+ individuals to suppress viral replication 
(188). However, the mechanism of this inhibition remains undefined, as presentation of peptides 
containing these KIR-associated polymorphisms by an MHC class I KIR ligand has not been 
demonstrated. The potential modulation of KIR and MHC class I interactions by MHC class I-
bound viral peptides during infection therefore warrants further investigation. 
We previously demonstrated that the binding of a common MHC class I molecule in the 
rhesus macaque, Mamu-A1*002, to the inhibitory Mamu-KIR3DL05 is stabilized by certain SIV 
peptides, but not by others (144). To investigate the functional implications of these findings and 
evaluate the hypothesis that these inhibitory peptides may serve as a mechanism of immune 
evasion to prevent killing of virus-infected cells by a subset of NK cells, we evaluated Mamu-
KIR3DL05+ NK cell killing of Mamu-A1*002+ TAP-inhibited cells pulsed with different SIV 
peptides. This approach allows interrogation of NK cell killing of cells that express the same 
MHC class I but present different peptides. Using this assay, we show that certain SIV peptides 
suppress the cytolytic activity of Mamu-KIR3DL05+ NK cells, and that the effect of an 
inhibitory peptide is dominant over non-inhibitory peptide when presented as part of a peptide 
mixture. In addition, Mamu-KIR3DL05+ NK cells are inhibited in the ability to suppress viral 
replication in Mamu-A1*002+ cells. These results suggest that inhibitory viral peptides may 
serve as a mechanism of immune evasion to prevent killing of infected cells by Mamu-
KIR3DL05+ NK cells. 
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3.4 - Materials and Methods 
Ethics statement 
The Indian origin rhesus macaques (Macaca mulatta) used in this study were housed and 
cared for at the New England Primate Research Center (NEPRC) in accordance with standards of 
the Association for Assessment and Accreditation of Laboratory Animal Care and the Harvard 
Medical School Animal Care and Use Committee. Animal experiments were approved by the 
Harvard Medical Area Standing Committee on Animals and conducted according to the 
principles described in the Guide for the Care and Use of Laboratory Animals (218). 
 
721.221-ICP47-A1*002 stable cell line 
Rhesus macaque Mamu-A1*002 cDNA was cloned into the pQCXIP retroviral vector 
(Clontech). This vector was cotransfected with pVSV-G (Clontech) into GP2-293 cells and 
supernatant was harvested two days post-transfection. The supernatant was centrifuged in 
Ultracel 50k filter centrifuge tubes (Millipore) to yield concentrated VSV-G pseudotyped MLV-
based particles. 721.221-ICP47 cells (238) were transduced by incubation with concentrated 
virus for 3 hours at 37˚C. Three days later, cells were placed under selection with 0.4 ug/mL 
puromycin (Invitrogen).  
 
NK cell expansion and cell culture 
PBMC (5 × 106 cells) were stimulated with 1 × 107 γ-irradiated K562 Clone 9.mbIL21 
cells (219) in a volume of 40 mL of RPMI 1640 (Invitrogen) supplemented with 10% FBS 
(Invitrogen), glutamine (Invitrogen), Primocin (InvivoGen), and 50 U/mL IL-2 (AIDS Research 
and Reference Reagent Program). On days 3 and 5 after culture, cells were resuspended in fresh 
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medium. The expanded NK cells were re-stimulated on day 7, and weekly thereafter, with 
additional γ-irradiated K562 Clone 9.mbIL21 cells at a 1:1 ratio. From day 7 onward, expanded 
cells were resuspended in fresh medium at 4 × 105 cells/mL 2-3 times weekly.  
 
NK cell sorting 
Expanded NK cell cultures were incubated with anti-CD3 Ab (clone 6G12) and T cells 
were depleted using pan-mouse IgG Dynabeads (Dynal Biotech). Mamu-KIR3DL05+ and  
-KIR3DL05- subsets were separated by FACS using a Mamu-A1*002 tetramer folded with 
Gag71-79 GY9 that binds Mamu-KIR3DL05 (144). NK cells were stained with PE-conjugated 
Mamu-A1*002-GY9 tetramer for 30 minutes at 37°C followed by staining with anti-CD3-Pacific 
Blue (clone SP34-2; BD Biosciences) and anti-NKG2A-APC (clone Z199; Beckman Coulter) or 
anti-NKG2A-Pacific Blue and anti-CD3-FITC (clone SP34; BD Biosciences) for 20 minutes at 
25°C. Tetramer+CD3-NKG2A+ and Tetramer-CD3-NKG2A+ subsets were sorted using a 
FACSAria (BD Biosciences). After sorting, these NK cells subsets were used immediately in a 
viral suppression assay or were stimulated with γ-irradiated K562 Clone 9.mbIL21 cells and 
maintained as described above. 
 
Calcein acetoxymethyl ester cytotoxicity assay 
Mamu-A1*002-binding SIV peptides (GenScript and Mimotopes) were pulsed onto 
721.221-ICP47-A1*002 cells overnight at 26°C in Hybridoma-Serum Free Medium (Invitrogen) 
to stabilize cell surface Mamu-A1*002-peptide complexes. An aliquot of 2 × 105 peptide-pulsed 
cells were then stained with a PE-conjugated pan-MHC class I specific antibody (clone W6/32; 
Dako) to verify this surface stabilization. The remaining peptide-pulsed cells were stained with 
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calcein acetoxymethyl ester (CAM; Invitrogen) at a 1:100 dilution for 1 hr at 26°C. CAM-
stained cells were washed and then incubated with Mamu-KIR3DL05+ or -KIR3DL05- NK cells 
for 4 hours at E:T ratios between 0.5:1 and 10:1. The release of CAM into the supernatant was 
measured using a fluorescent plate reader (excitation 485 nm, absorption 530 nm). Percent 
specific lysis was calculated as (test release – spontaneous release) / (maximum release – 
spontaneous release). 
 
Viral suppression assay 
The target cells were prepared by depletion of CD8+ cells from PBMC by treatment with 
CD8-Dynabeads (Dynal Biotech) followed by ConA-activation (5 µg/ml) in RPMI 1640 
supplemented with 10% FBS, glutamine, HEPES (Invitrogen), and Primocin (R10) for 4 days. 
On the day of the assay, 2 × 106 target cells were infected with 100 ng p27 SIVmac239 in minimal 
volume for 3 hours at 37°C, then washed. Mamu-KIR3DL05+ and -KIR3DL05- NK cell subsets 
were sorted as described above and were incubated with 2 × 104 SIV-infected autologous CD4+ 
target cells in 200 uL R10 + 20 U/mL IL-2 in duplicate wells at a 3:1 E:T ratio. On days 3, 5, 7, 
and 9/10, 50 uL of supernatant was sampled with replacement. SIV titer was determined by SIV 
p27 Antigen Capture Assay (Advanced Bioscience Laboratories). Area under the curve 
calculated in Prism 6 (GraphPad). 
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3.5 - Results 
Mamu-A1*002-SIV peptide complexes differentially inhibit Mamu-KIR3DL05+ NK cells 
We previously demonstrated that Mamu-A1*002 SIV tetramers folded with some SIV 
peptides, but not others, bind Mamu-KIR3DL05 (144). To evaluate the functional implications 
of these interactions, we developed a peptide-pulsing cytotoxicity assay. MHC class I-deficient 
721.221 target cells were transduced with retroviral vectors expressing Mamu-A1*002 and 
ICP47, a herpes simplex virus 1 protein that inhibits the transporter associated with antigen 
processing (TAP) (238). Since TAP is necessary for translocation of endogenously-derived 
peptides from the cytosol into the ER for loading onto nascent MHC class I molecules, MHC 
class I molecules expressed by 721.221-ICP47 cells are empty and rapidly internalized from the 
cell surface. Therefore, 721.221-ICP47-A1*002 cells express low levels of surface MHC class I 
molecules. Because Mamu-A1*002 is not loaded with self-peptide on these cells, the addition of 
exogenous peptide that binds Mamu-A1*002 ensures that the vast majority of the MHC class I 
molecules on the cell surface are loaded with this particular peptide. Peptide binding is verified 
by increased MHC class I surface expression, as Mamu-A1*002 is stabilized once loaded with 
peptide. This approach allows interrogation of NK cell responses to target cells expressing the 
same MHC class I molecule but presenting different peptides.  
721.221-ICP47-A1*002 cells were pulsed overnight with CD8+ T cell SIV epitopes 
bound by Mamu-A1*002: Gag71-79 GY9, Nef159-167 YY9, Env788-795 RY8, Vif89-97 IW9, Env760-768 
SY9, or Nef169-177 KL9. Peptide-pulsed cells were then stained with CAM and incubated with 
sorted Mamu-KIR3DL05+ or -KIR3DL05- NK cells from the same animal that had been 
expanded on γ-irradiated K562 Clone 9.mbIL21 cells (219). Mamu-KIR3DL05- NK cells killed 
all peptide-pulsed cells to a similar extent (Figure 3.1A). In contrast, Mamu-KIR3DL05+ NK 
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cells were inhibited by target cells pulsed with GY9, YY9, or RY8, but not by target cells pulsed 
with IW9, SY9, or KL9. This selective inhibition was observed in experiments with cells from 
four different animals (Figure 3.1B) and was not caused by differences in MHC class I surface 
expression as all pulsed peptides stabilized Mamu-A1*002 to a similar extent (Figure 3.1C). 
These results are consistent with our previously published binding data in which Mamu-A1*002 
tetramers folded with GY9, YY9, or RY8, but not IW9, bound to Mamu-KIR3DL05*008 (144). 
Figure 3.1. Mamu-A1*002 inhibits Mamu-KIR3DL05+ NK cells when presenting SIV peptides 
GY9, YY9, and RY8, but not IW9, SY9, or KL9. (A) Mamu-KIR3DL05+ and -KIR3DL05- NK 
cells from the same animal were coincubated with 721.221-ICP47-A1*002 cells pulsed with the 
SIVmac239 Mamu-A1*002 epitopes indicated. Killing of target cells at the indicated 
effector:target (E:T) ratios was evaluated by release of CAM from target cells into the culture 
supernatant. % Specific Lysis is defined as (test release – spontaneous release) / (maximum 
release – spontaneous release). Results are representative of those obtained with expanded cells 
from three different animals and the compiled results for Mamu-KIR3DL05+ NK cells from 
these animals at a 5:1 E:T ratio are presented in (B). Error bars indicate + 1 SD. Asterisks 
indicate a significant difference (****p<0.001 by ANOVA with Dunnett’s test) between 
coincubation with unpulsed 721.221-ICP47-A*02 cells (No peptide) and those pulsed with the 
indicated peptide at all E:T ratios shown. (C) Stabilization of A1*002 on the 721.221-ICP47-
A1*002 cell surface by peptide pulsing was verified by staining with W6/32 antibody and was 
comparable for all epitopes. GY9 2N9G is a non-A1*002-binding peptide control. 
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To identify inhibitory and non-inhibitory peptides among the 75 SIV peptides previously 
shown to bind to Mamu-A1*002 (239), 721.221-ICP47-A1*002 cells pulsed with each of these 
peptides were incubated with Mamu-KIR3DL05+ or -KIR3DL05- NK cells from the same animal 
in a CAM cytotoxicity assay. All peptides stabilized Mamu-A1*002 surface expression to 
approximately the same degree (Supplemental Figure 3.1) and Mamu-KIR3DL05- NK cells 
lysed all pulsed cells to a similar extent (Supplemental Figure 3.2). However, cells pulsed with 
28 of the 75 peptides significantly inhibited killing by Mamu-KIR3DL05+ NK cells (Figure 3.2). 
Among these inhibitory peptides are 7 epitopes to which a CD8+ T cell response has been 
previously identified in SIV-infected animals, confirming that these epitopes are presented in 
vivo. The peptides in Figure 3.2 are presented in order of binding affinity for Mamu-A1*002. 
Notably, the four highest-affinity Mamu-A1*002-binding SIV peptides are inhibitory and 
include the immunodominant CD8+ T cell eptiopes Nef YY9, Env RY8, and Gag GY9. Due to 
their high affinity for Mamu-A1*002, these inhibitory peptides may be presented at a higher 
frequency on the cell surface than other viral peptides, and may therefore be more likely to have 
an effect upon Mamu-KIR3DL05+ NK cell killing of infected cells. 
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Figure 3.2. Twenty-eight of 75 Mamu-A1*002-binding SIV peptides inhibit Mamu-KIR3DL05+ 
NK cells. Mamu-KIR3DL05+ NK cells were coincubated at a 5:1 E:T ratio with 721.221-ICP47-
A1*002 cells pulsed with the Mamu-A1*002-binding SIVmac239 peptides indicated. Peptides 
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Figure 3.2 (Continued). are ordered by affinity of peptide binding to Mamu-A1*002 from 
highest affinity to lowest and defined CD8+ T cell epitopes are shown in purple. Killing of target 
cells was evaluated by release of CAM from target cells into the culture supernatant. Compiled 
results are from experiments with expanded cells from three different animals and error bars 
indicate + 1 SD. Asterisks indicate a significant difference (*p<0.05, **p<0.01, ***p<0.005, 
****p<0.001 by ANOVA with Dunnett’s test) between coincubation with unpulsed 721.221-
ICP47-A1*002 cells (No peptide) and those pulsed with the indicated peptide. Stabilization of 
Mamu-A1*002 on the 721.221-ICP47-A1*002 cell surface by peptide pulsing was verified by 
staining with W6/32 antibody and was comparable for all peptides (Supplemental Figure 3.1). 
GY9 2N9G is a non-A1*002-binding peptide control. 
 
Changes in C-terminal residues of Mamu-A1*002-presented SIV peptides can alter inhibitory 
phenotype 
Crystal structures of KIR in complex with ligands have shown that KIRs bind over the C-
terminus of MHC class I-presented peptide (145, 150-152). To evaluate the residues responsible 
for inhibitory and non-inhibitory phenotypes of the SIV peptides described above, peptides with 
substitutions at C-terminal residues were produced for three inhibitory peptides and one non-
inhibitory peptide that bind to Mamu-A1*002 with high affinity: GY9, YY9, RY8, and IW9, 
respectively. 721.221-ICP47-A1*002 cells pulsed with variant peptides were used as target cells 
in CAM cytotoxicity assays with Mamu-KIR3DL05+ and -KIR3DL05- NK cells from the same 
animal. Mamu-A1*002 stabilization by peptide pulsing was similar for all peptides tested 
(Supplemental Figure 3.3). Mamu-KIR3DL05- NK cells killed all targets to a similar extent, but 
Mamu-KIR3DL05+ NK cells were inhibited to varying degrees by cells pulsed with select 
variant peptides.  
GY9 residue 8 is critically important for facilitating interaction with Mamu-KIR3DL05. 
A leucine to alanine substitution at this position (GY9 L8A) decreased the inhibitory capacity of 
the peptide, whereas GY9 with a leucine to tryptophan substitution at the same position (GY9 
L8W) was completely non-inhibitory (Figure 3.3A). Variant peptides with a leucine to 
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phenylalanine or tyrosine substitution at residue 8 (GY9 L8F and GY9 L8Y, respectively) were 
also non-inhibitory (Supplemental Figure 3.4). The effect of residue 8 substitutions upon Mamu-
KIR3DL05+ NK cell inhibition by GY9-pulsed cells was reproducible in experiments with NK 
cells from three different animals (Figure 3.3B). In contrast to the unique effect of variants at 
GY9 residue 8, YY9 residues 6 through 8 all affect its inhibitory phenotype. Alanine substitution 
at position 6 (YY9 G6A) resulted in a less inhibitory peptide, whereas an alanine subsitution at 
position 8 (YY9 R8A) rendered a more inhibitory peptide (Figure 3.3C-D). Decreased inhibition 
was observed with tryptophan subsitution at YY9 residue 6 or 7 (YY9 G6W, YY9 I7W, 
respectively) and tryptophan subsitution at position 8 (YY9 R8W) abrogated inhibition of 
Mamu-KIR3DL05+ NK cells in response to YY9-pulsed target cells. Corresponding to its shorter 
length, RY8 residue 7 is most important for Mamu-KIR3DL05 recognition of Mamu-A1*002-
RY8 complexes, as tryptophan substitution at this position (RY8 V7W), and to a lesser extent 
residue 6 (RY8 R6W), decreases interaction with Mamu-KIR3DL05 (Figure 3.3E-F). 
Conversely, double substitutions at residue 8 and 9 in the non-inhibitory peptide IW9 (IW9 
F8A/W9Y) confer an inhibitory phenotype (Figure 3.3G-H). These results demonstrate that C-
terminal residues of all four SIV peptides tested govern Mamu-KIR3DL05 recognition of Mamu-
A1*002. The precise characteristics required of an inhibitory peptide are not obvious, but bulky 
residue substitutions such as tryptophan at the penultimate peptide residue 7 or 8 consistently 
disrupted the Mamu-A1*002-KIR3DL05 interaction.   
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Figure 3.3. Substitutions at peptide residues 6 through 9 can alter inhibitory capacity. Mamu-
KIR3DL05- and -KIR3DL05+ NK cells from the same animal were coincubated with 721.221-
ICP47-A1*002 cells pulsed with variants of GY9 (A), YY9 (C), RY8 (E), and IW9 (G) as 
indicated. Killing of target cells at the indicated E:T ratios was evaluated by release of CAM 
from target cells into the culture supernatant. Results are representative of those obtained with 
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Figure 3.3 (Continued). expanded cells from at least two different animals and the compiled 
results from these animals are presented in (B, D, F, and H), respectively. Error bars indicate + 1 
SD. Asterisks indicate a significant difference (*p<0.05, ***p<0.005, ****p<0.001 by ANOVA 
with Dunnett’s test) between coincubation with 721.221-ICP47-A1*002 cells pulsed with the 
wildtype epitope and those pulsed with the indicated epitope variant at all E:T ratios shown. 
Stabilization of Mamu-A1*002 on the 721.221-ICP47-A1*002 cell surface by peptide pulsing 
was verified by staining with W6/32 antibody and was comparable for all peptides 
(Supplemental Figure 3.3). GY9 2N9G is a non-A1*002-binding peptide control. 
 
Remarkably, both GY9 and YY9 have been crystallized in complex with Mamu-A1*002. 
The crystal structure of Mamu-A1*002 bound to GY9 shows that residue 8 protrudes from the 
peptide binding cleft (240). In silico substitution at this position to alanine or tryptophan alters 
the surface over which Mamu-KIR3DL05 is expected to bind (Figure 3.4A). The reduced 
inhibitory capacity of GY9 L8A may be due to the absence of a necessary contact with the 
leucine sidechain that protrudes in the wildtype epitope. Conversely, the bulky protrusion of a 
tryptophan sidechain at this position may sterically hinder interaction with Mamu-KIR3DL05, 
leading to the non-inhibitory phenotype of the GY9 L8W peptide. Modeling the critical 
disruptive trypophan substitutions at position 7 or 8 onto the Mamu-A1*002-YY9 crystal 
structure (241) demonstrates that the substituted sidechain at these two positions is also predicted 
to protrude out of the peptide-binding cleft (Figure 3.4B), perhaps thereby preventing interaction 
with Mamu-KIR3DL05. These structures suggest that Mamu-KIR3DL05 recogntion of Mamu-
A1*002 is not sensitive to all substitutions in C-terminal peptide residues, but more specifically 
to substitutions in residues that have a sidechain protruding from the peptide-binding cleft and 
are therefore accessible for KIR interaction.  
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Figure 3.4. Structural implications of peptide modifications of GY9 and YY9. (A) Crystal 
structure of Mamu-A1*002 (blue) loaded with GY9 (yellow) (240). Alanine and tryptophan 
substitutions at peptide position 8, highlighted in red, are modeled. (B) Crystal structure of 
Mamu-A1*002 (blue) loaded with YY9 (yellow) (241). Tryptophan substitutions at peptide 
positions 7 and 8, highlighted in red, are modeled.  
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The inhibitory peptide GY9 dominates over its non-inhibitory variant in peptide mixtures to 
prevent lysis by Mamu-KIR3DL05+ NK cells 
To determine whether a viral inhibitory epitope exerts an inhibitory effect when co-
presented with non-inhibitory peptide, as would occur on the infected cell surface, peptide 
mixture experiments were conducted. CAM cytotoxicity assays were performed with 721.221-
ICP47-A1*002 cells pulsed with peptide mixtures of GY9 and GY9 L8W. When present at 25% 
of the total peptide concentration, GY9 exerted nearly its full inhibitory capacity in preventing 
killing by Mamu-KIR3DL05+ NK cells (Figure 3.5A). This result was consistent in experiments 
with NK cells from three different animals (Figure 3.5B). To investigate whether the inhibitory 
effect of GY9 could be removed by further dilution, 721.221-ICP47-A1*002 cells were pulsed 
with a mixture 0.375 µM GY9 L8W and decreasing concentrations of GY9 beginning with the 
lowest GY9 concentration tested in the previous experiment. Surprisingly, GY9 exerts a 
detectable inhibitory effect even when diluted to concentrations lower than 10% of the peptide 
mixture (Figure 3.5C). Similar results were observed with peptide mixtures of RY8 and the non-
inhibitory variant RY8 7W (Figure 3.5D-F) The dominance of inhibitory peptides GY9 and RY8 
support the hypothesis that viral inhibitory peptides may prevent lysis by KIR-expressing subsets 
of NK cells when presented on an infected cell surface as part of a peptide mixture.  
	  73	  
Figure 3.5. Dominance of an inhibitory peptide over the non-inhibitory variant. Mamu-
KIR3DL05+ NK cells were coincubated with 721.221-ICP47-A1*002 cells pulsed with mixtures 
of GY9 and GY9 8W (A) or RY8 and RY8 7W (D) at the µM concentrations indicated. Killing 
of target cells at the indicated E:T ratios was evaluated by release of CAM from target cells into 
the culture supernatant. Results are representative of those obtained with expanded cells from at 
least two different animals and the compiled results from these animals are presented in (B) and 
(E), respectively. Error bars indicate + 1 SD. Asterisks indicate a significant difference (*p<0.05, 
****p<0.001 by two-way ANOVA with Dunnett’s test) between coincubation with 721.221-
ICP47-A1*002 cells pulsed with GY9 or RY8, respectively, and those pulsed with the indicated 
peptide mixture at all E:T ratios shown. Mamu-KIR3DL05+ NK cells were coincubated at a 5:1 
E:T ratio with 721.221-ICP47-A1*002 cells pulsed with the indicated concentration GY9 in a 
mixture with 0.375 µM GY9 8W (C) or with the indicated concentration of RY8 in a mixture 
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Figure 3.5 (Continued). with 3.75 µM RY8 7W (F). Killing of target cells was evaluated by 
release of CAM from target cells into the culture supernatant. Stabilization of A1*002 on the 
721.221-ICP47-A1*002 cell surface by peptide pulsing was verified by staining with W6/32 
antibody and was comparable for all peptide mixtures (Supplemental Figure 3.5). GY9 2N9G is 
a non-A1*002-binding peptide control. 
 
Mamu-KIR3DL05+ NK cells do not fully suppress SIV replication in Mamu-A1*002+ CD4+ T 
cells 
Mamu-KIR3DL05 ligand recognition on SIV-infected cells could be affected by Nef-
mediated downregulation of Mamu-A1*002 (99). To investigate whether Mamu-KIR3DL05+ 
NK cells are selectively inhibited in their ability to suppress SIV replication despite Nef-
mediated downregulation of Mamu-A1*002, we carried out viral suppression assays. Viral 
replication was monitored in autologous CD4+ T cells incubated with sorted Mamu-KIR3DL05+ 
or -KIR3DL05- NK cells. In assays using cells from Mamu-A1*002- animals, both NK cell 
subsets suppressed viral replication to a similar extent (Figure 3.6A). In contrast, viral replication 
in the presence of Mamu-KIR3DL05+ NK cells was greater than in the presence of Mamu-
KIR3DL05- NK cells for experiments with cells from Mamu-A1*002+ animals. This difference 
was consistent in experiments performed with cells from three different Mamu-A1*002+ animals 
(Figure 3.6B). The marked inhibition of Mamu-KIR3DL05+ NK cells, even when Mamu-
A1*002 is downregulated by Nef, may be caused in part by the presence of viral peptides that 
promote Mamu-KIR3DL05 recognition of Mamu-A1*002.  
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Figure 3.6. Mamu-KIR3DL05+ NK cells are inhibited have limited ability to suppress SIV 
replication in Mamu-A1*002+ cells. (A) Mamu-KIR3DL05+ and -KIR3DL05- subsets of CD3-
NKG2A+ sorted primary NK cells were incubated with SIV-infected autologous CD4+ target 
cells (2×104 cells) in duplicate wells at a 3:1 E:T ratio. SIV replication in cells from Mamu-
A1*002- and -A1*002+ animals was determined by measuring the accumulation of SIV p27 in 
the culture supernatant by ELISA. Each graph is representative of results obtained with cells 
from three different animals and the compiled results from these animals are presented in (B) 
where AUC is area under the curve. Error bars indicate + 1 SEM, (*p<0.05 by paired t-test).  
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3.6 - Discussion 
The importance of KIR-MHC class I interactions in viral infections has been established 
by genetic studies associating expression of certain KIR and MHC class I molecules with control 
of viral infections including HIV, HBV, and HCV (176, 177, 194, 196, 242). However, MHC 
class I-bound peptide can alter KIR ligand recognition, and little is known about the ability of 
viral peptides to alter inhibition of KIR-expressing NK cell subsets during infection. In this 
study, we identified 28 SIV Mamu-A1*002-binding peptides, including three immunodominant 
CD8+ T cell epitopes, that allow ligand recognition by Mamu-KIR3DL05 and inhibit NK cells 
expressing this KIR. We determined that substitutions at C-terminal positions in these epitopes, 
such as the introduction of tryptophan at position 7 or 8, can disrupt Mamu-KIR3DL05 ligand 
recognition. When presented as part of a peptide mixture, an inhibitory peptide was dominant 
over a non-inhibitory peptide and prevented target cell lysis by Mamu-KIR3DL05+ NK cells. 
Finally, Mamu-KIR3DL05+ NK cell suppression of viral replication in autologous CD4+ T cells 
was selectively inhibited in assays with cells from Mamu-A1*002+ animals. These results 
suggest that viral peptides that alter KIR recognition of MHC class I ligands may affect the 
activity of KIR-expressing subsets of NK cells, even when presented as a part of a peptide 
mixture and under conditions of partial Nef-mediated MHC class I downregulation.  
This study is the first analysis of differential KIR inhibition mediated by the complete set 
of viral peptides presented by a single MHC class I molecule. Although only 28 of the 75 
peptides tested were inhibitory, the four SIV peptides that bind Mamu-A1*002 with the highest 
affinity all inhibited Mamu-KIR3DL05+ NK cells very effectively. This enhanced inhibition was 
not a direct effect of better Mamu-A1*002 binding, as all peptides stabilized Mamu-A1*002 cell 
surface expression to a similar extent. These four high-affinity peptides may more readily bind 
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Mamu-A1*002 during MHC class I loading and be presented at a greater frequency on an 
infected cell surface, thereby increasing the likelihood that they have an effect on Mamu-
KIR3DL05+ NK cell activity in vivo. Furthermore, among these interactions, the Mamu-
A1*002-KIR3DL05 interaction promoted by Gag GY9 is of particularly high affinity. Mamu-
A1*002 tetramer folded with this peptide can stain Mamu-KIR3DL05 on primary NK cells 
(144), whereas other rhesus and human tetramers tested can only stain KIR that are 
overexpressed. High affinity interactions between Mamu-KIR3DL05 and Mamu-A1*002 
presenting peptides such as GY9 may play a role in preventing Mamu-KIR3LD05+ NK cell 
activation in response to SIV-infected cells.  
Although Mamu-A1*002 is downregulated by Nef in SIV-infected cells (99), the reduced 
capacity of Mamu-KIR3DL05+ NK cells from Mamu-A1*002+ animals to suppress viral 
replication in autologous T cells demonstrates that despite partial downregulation, there is still 
sufficient Mamu-A1*002 on the infected cell surface to inhibit Mamu-KIR3DL05+ NK cell 
activity. This observation contrasts with human KIR3DL1+ NK cells from HLA-B*57 
individuals, which are more active than KIR3DL1- NK cells in response to HIV-infected 
autologous cells, presumably due to lost HLA-B*57 recognition as a result of Nef expression 
during infection (183). These KIRs also differ in their effect upon immunodeficiency virus 
infection: human KIR3DL1 is protective in HIV infection (177) and Mamu-KIR3DL05 is 
associated with higher viral load in SIV-infected animals (186). The activity of these NK cell 
subsets suggests that although NK cells expressing some inhibitory KIR, such as KIR3DL1, are 
activated by infected cells, Mamu-KIR3DL05+ NK cells have a reduced capacity to respond to 
SIV-infected cells, perhaps in part due to Mamu-A1*002 presentation of inhibitory peptides 
including Gag GY9. 
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We observed that an inhibitory peptide has a dominant effect in a peptide mixture and 
prevented activation of Mamu-KIR3DL05+ NK cells. In the context of self-tolerance, this 
dominant effect could prevent errant killing of healthy autologous cells. In general, loss of KIR 
binding to self-MHC class I molecules can lead to NK cell activation. If non-inhibitory peptide 
present as a small fraction of total peptide on a healthy cell surface could prevent Mamu-
KIR3DL05+ NK cell inhibition by Mamu-A1*002, then NK cell killing could result from 
relatively small changes in the peptide repertoire that may otherwise be harmless. However, a 
previous study looking at two HLA-Cw*0102-presented peptides, VAP-FA, an inhibitory 
peptide, and VAP-DA, an antagonistic peptide, found that there was a linear change in activation 
of KIR2DL2/2DL3+ NK cells pulsed with mixtures of the two peptides (157). The VAP-DA 
antagonistic peptide increased NK cell activity even when present as 10% of the peptide mixture, 
whereas in this study we only observed an increase in NK cell activity when the non-inhibitory 
peptide made up 75% or more of the peptide mixture.  
The discrepancy between these results may reflect a fundamental difference in the 
importance of peptide for ligand recognition by KIR2DL and Mamu-KIR3DL molecules. 
Among the available crystal structures, HLA-Cw3 in complex with KIR2DL2 (150) and HLA-
B*57 in complex with KIR3DL01*001 (152), respectively, most closely resemble the KIR-
ligand complexes involved in these experiments. Although both structures indicate a KIR contact 
at position 8 of the MHC class I-bound peptide, KIR2DL2 recognition is more sensitive to amino 
acid substitutions at this position. The KD of KIR2DL2 binding to HLA-C is more drastically 
altered by these substitutions than is the KD of KIR3DL01*001 binding to HLA-B*57 (150, 
152), perhaps indicating a higher peptide-dependence for this interaction and greater sensitivity 
to antagonism. However, it is unclear whether this structural difference also applies more 
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broadly to KIR2DL2 recognition of HLA-Cw*0102 and Mamu-KIR3DL05 recognition of 
Mamu-A1*002. The difference between the inhibitory peptide dominance in these two studies 
may also be due to the nature of the peptide variants examined. We introduced bulky residues at 
positions 7 or 8 to potentially disrupt the interaction with Mamu-KIR3DL05, whereas the 
antagonism caused by the VAP-DA peptide relies on a difference in charge to alter interaction 
(157). Furthermore, the peptide antagonist VAP-DA induces KIR clustering on the NK cell 
surface, which normally occurs during NK cell recognition of ligand, but in the case of the 
antagonistic peptide no signal is transduced from the ITIM (157, 243). This antagonist peptide-
MHC class I complex is therefore referred to as a low-affinity binder of KIR3DL2 (243), and 
may represent a qualitatively different type of disruption than that introduced by bulky residues 
in our study.  
The role of peptide polymorphisms in modulating interaction with KIR and the activity of 
KIR-expressing NK cell subsets has recently been demonstrated in the context of HIV infection. 
HIV polymorphisms in Vpu and Env associated with KIR2DL2 have been shown to decrease the 
capacity of NK cells from KIR2DL2+ individuals to suppress viral replication and increase the 
binding of a KIR2DL2-Fc fusion construct to infected cells, though the mechanism for this effect 
has not been defined (188). Conversely, a CD8+ T cell escape variant in a Gag epitope presented 
by HLA-Cw*0102 decreased KIR2DL2 binding to peptide-pulsed cells (191). HLA-C ligands of 
KIR2DL2 molecules are not downregulated by Nef. In contrast, the KIR ligand we examine in 
this paper is downregulated by Nef, and it is therefore surprising that this downregulated MHC 
class I molecule can still diminish the ability of Mamu-KIR3DL05+ NK cells to suppress viral 
replication and kill virus-infected cells. The prevalence of inhibitory peptides among the highest 
affinity Mamu-A1*002-binding SIV peptides may contribute to this observation, and suggest 
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that perhaps viral mutations in peptides bound by other downregulated MHC class I molecules 
that promote binding to inhibitory KIR may compensate for Nef-mediated MHC class I 
downregulation, thereby evading the NK cell immune response.  
Previous studies of the effect of MHC class I-bound peptide upon interaction with KIR 
have been limited to the HLA molecules endogenously expressed by T2 cells, a TAP-deficient 
cell line used in many peptide-pulsing experiments (157, 184, 191). While it is possible to 
transduce these cells to express additional MHC class I molecules, the peptide-mediated 
stabilization cannot be attributed to a specific MHC class I molecule when multiple are 
expressed. The use of 721.221-ICP47 cells in place of T2 cells provides more flexibility for 
future studies in looking at peptides bound by any MHC class I molecule. This assay will be of 
particular use for evaluating whether MHC class I-bound peptides that increase recognition by 
KIR2DL2 are the mechanism by which KIR2DL2-associated polymorphisms promote KIR2DL2 
binding to infected cells, and for investigating whether KIR play a role in the HIV and SIV 
control associated with certain MHC class I molecules.  
In conclusion, we used a novel TAP-inhibited peptide-pulse cytotoxicity assay to 
investigate the activity of Mamu-KIR3DL05+ NK cells against Mamu-A1*002+ cells presenting 
different SIV peptides. Among the inhibitory peptides were immunodominant CD8+ T cell 
epitopes. Peptide mixture assays of inhibitory peptides with non-inhibitory variants that had a 
tryptophan substitution at residue 7 or 8 demonstrated that the inhibitory peptide was dominant at 
low concentrations and prevented killing of pulsed cells by Mamu-KIR3DL05+ NK cells. Virus 
suppression by Mamu-KIR3DL05+ NK cells was selectively inhibited in cells from Mamu-
A1*002+ animals despite Nef-mediated downregulation of Mamu-A1*002. Inhibitory viral 
peptides including GY9, YY9, and RY8 may contribute to the decreased activity of Mamu-
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KIR3DL05+ NK cells by promoting recognition of Mamu-A1*002 on the surface of SIV-
infected cells by this inhibitory KIR. 
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Chapter 4 
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4.1 - Conclusions 
The second chapter of this dissertation defined several ligands for the prevalent rhesus 
macaque KIR Mamu-KIR3DL01. This study suggests that KIR recognition of MHC-B Bw4 
molecules has been maintained since humans and macaques last shared a common ancestor. 
Moreover, mutational analysis revealed that many of the determinant residues for Mamu-
KIR3DL01 ligand recognition are also essential for human KIR3DL1 binding (152), which is 
surprising because these two KIR are not related and do not have an orthologous relationship. 
One of the severe limitations of studying rhesus macaque KIR and NK cell populations is that 
few staining reagents are available to identify KIR-expressing NK cell subsets. This work 
showed that most allotypes of Mamu-KIR3DL01 can be stained by a pan-human-KIR2D 
antibody. The Mamu-KIR3DL01 specificity of this antibody doubles the number of rhesus 
macaque KIR that can be identified by antibody staining. Together with the definition of ligands 
for this KIR, this study will be foundational for further studies of the frequency of KIR-
expressing NK cell populations in vivo. 
The third chapter of this dissertation demonstrated that approximately one-third of SIV 
peptides that bind Mamu-A1*002 promote interaction with Mamu-KIR3DL05 and inhibit 
Mamu-KIR3DL05+ NK cells. A novel cytotoxicity assay approach was used to evaluate these 
peptides by monitoring NK cell killing of peptide-pulsed cells transduced with ICP47, which 
inhibits TAP, and Mamu-A1*002. This assay allows interrogation of NK cell activity in response 
to cells that express the same MHC class I molecule, Mamu-A1*002, but present different 
peptides. Inhibitory peptides were dominant and prevented killing by Mamu-KIR3DL05+ NK 
cells when presented in a mixture with non-inhibitory variants that had a tryptophan substitution 
at residue 7 or 8. Furthermore, despite Nef-mediated downregulation of Mamu-A1*002, viral 
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suppression by Mamu-KIR3DL05+ NK cells was selectively inhibited with cells from Mamu-
A1*002+ animals. These results suggest that inhibitory viral peptides that promote Mamu-
KIR3DL05 binding to Mamu-A1*002 may diminish the activity of Mamu-KIR3DL05+ NK cells, 
even when these peptides are presented as a part of a peptide mixture and under conditions of 
partial Nef-mediated Mamu-A1*002 downregulation. 
 
4.2 - Coevolution of KIR and MHC class I 
 Examination of KIR and MHC class I molecules in primate species illustrates the 
coevolution of these receptors and ligands. This relationship is evident in the differences in KIR 
and MHC class I repertoires between macaques and humans. Corresponding to the lack of an 
HLA-C orthologue in rhesus macaques (207), these animals also lack the KIR2D molecules that 
recognize MHC-C molecules (211). More strikingly, the emergence of an HLA-C orthologue in 
orangutans, Popy-C, coincides with the expression of KIR2D molecules (201). Notably, these 
KIR2D expressed by orangutans all recognize C1 MHC-C molecules that have an asparagine at 
position 80, corresponding to the epitope present on Popy-C molecules, whereas human KIR2D 
molecules can recognize MHC-C with either a C1 or a C2 epitope. However, there is also an 
orangutan KIR that has dual specificity for both C1 and C2 Popy-C molecules (244). The 
presence of this KIR in the absence of a Popy-C C2 ligand suggests that KIR may provide 
additional selective pressure for the development of MHC class I ligands that they recognize.  
 Although KIR and MHC class I are coevolving, there may also be functional advantages 
to having MHC class I molecules that are not recognized by KIR. The second chapter of this 
dissertation demonstrated that KIR recognition of Bw4 ligands occurs in both humans and rhesus 
macaques by a largely similar pattern of recognition (245). However, HLA-B molecules with the 
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alternate Bw6 motif are not recognized by KIR in humans. In contrast, Mamu-KIR3DL05 
recognizes two Bw6-like ligands in rhesus macaques, Mamu-A1*002 and -A3*1303 (144). A 
potential advantage for humans in having many MHC class I molecules, including Bw6 
molecules, that are not KIR ligands could arise from allowing greater variation between 
individuals in the number of liganded KIRs expressed. If, for example, an individual expressed 
two Bw6 molecules, any KIR3D molecules that recognize HLA-B Bw4 molecules will not have 
ligands. Although expressing some KIR in conjunction with their MHC class I ligands is 
protective in viral infection, these interactions may be disadvantageous for other NK cell 
functions. The balancing act that exists in KIR immunogenetics is demonstrated by the 
maintenance of two types of KIR haplotypes in humans: haplotype A, which is advantageous in 
infection, and haplotype B, containing more activating KIR, which is advantageous in 
reproduction (246). Under such complicated selection, coevolution of KIR and MHC class I 
molecules may dictate that some MHC class I remain unrecognized by KIR. 
 
4.3 - Specificity and NK cells  
SIV peptide modulation of Mamu-A1*002 recognition by Mamu-KIR3DL05 contributes 
to a growing body of literature suggesting that NK cell responses are not as innate and non-
specific as originally thought. Canonical innate immune responses are not antigen-specific, but 
instead provide non-specific protection from pathogens. In contrast, the peptide preference in 
inhibitory KIR ligand recognition has been well-documented (142, 146, 156, 157, 160, 233-236) 
and an antagonistic peptide may activate NK cells by altering ligand recognition by an inhibitory 
KIR recognition (157). Instead of a non-specific response to the absence of MHC class I 
expression as “missing self” (104), this peptide-dependent method of NK cell activation suggests 
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the recognition of “altered self” wherein a change in the peptides presented by an MHC class I 
molecule can affect KIR recognition and NK cell activity. The association of HIV 
polymorphisms with the expression of certain KIRs suggests that these peptide-selective KIR-
MHC class I interactions are important during viral infection, although the mechanism of 
selection for these viral polymorphisms has not yet been demonstrated (188). Furthermore, NK 
cells can respond to HIV peptides (247), perhaps due to a mechanism involving recognition of 
presented viral peptides as altered self. In NK cell development KIR are expressed stochastically 
until an NK cell is sufficiently inhibited by self-MHC class I (132), which presumably includes 
the normal repertoire of self-peptides presented by that MHC class I molecule. Thus, peptide-
mediated NK cell activation may be specific to non-self or unhealthy cell states in which the 
regular peptide presentation is altered and affects KIR recognition of ligands. Although KIR do 
not have diversity analogous to that provided by genetic rearrangement of the T cell receptor, the 
high degree of KIR polymorphism combined with the effect of MHC class I-bound peptide upon 
KIR recognition create an antigen-specificity of another sort.  
Another facet of the specificity of NK cells is the demonstrated ability of these cells to 
develop antigen-specific memory responses in some cases. This phenomenon has occurred with 
Ly49H+ NK cells that recognize MCMV-infected cells by m157 expression and can generate a 
secondary immune response (248) and with liver NK cells that mediate a contact hypersensitivity 
response to haptens (249) and antigens from influenza, vasicular stomatitis virus, and HIV (250). 
These studies indicate that NK cells can develop memory to a broad range of antigens, but the 
receptors responsible for the viral and hapten memory have not been identified. Notably, the 
expression of Ly49 receptors is not altered in these memory cells, and memory populations can 
be developed after sensitization in multiple mouse strains that have different Ly49 and MHC 
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class I backgrounds (250). These characteristics suggest that MHC class I recognition by NK cell 
receptors is not the mechanism for memory development in this system. These memory-
generating experiments have all been performed in mice and it has not yet been determined if 
primate NK cells can produce similar memory responses. However, it is important to note that 
many of these murine memory NK cell responses are specific to liver NK cells that express the 
homing marker CXCR6 (250). It would be difficult to isolate similar tissue-resident NK cell 
populations from humans for experiments, and investigation of tissue-resident memory NK cell 
responses in higher animals may therefore be most effective in a non-human primate models like 
the rhesus macaque. 
 
4.4 - Future Directions 
 Because so few rhesus macaque KIR ligands have been defined, future studies must 
continue to determine which KIR and MHC class I molecules interact. The system used in this 
dissertation to detect ligand for Mamu-KIR3DL01 is quite resource-intense, involving sorting 
and lengthy culture of primary cells. An advantage of working with primary NK cells is that they 
express endogenous levels of KIRs. In contrast, stable cell lines would over-express KIR and 
may therefore be inhibited by weak-binding ligands that would not inhibit KIR on primary NK 
cells. However, as a general method of screening for KIR ligands, the use of primary NK cells is 
terribly restricted by the availability of specific staining reagents for rhesus macaque KIRs. To 
date, only Mamu-KIR3DL05 and -KIR3DL01, the KIRs examined in this study and for which 
ligands have been identified, can be specifically stained with tetramer or antibody (144, 230, 
245). Other mouse monoclonal antibodies have been generated against rhesus macaque KIR, but 
the utility of these antibodies is limited because they cross-react with with multiple KIRs (230). 
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As an alternative to primary NK cells, in light of the limitations, a more scalable approach for 
KIR ligand identification could evaluate the cytotoxicity of NK cell lines transduced with 
distinct KIRs against a panel of MHC class I-expressing cell lines. However, our attempts to 
produce these NK cell lines have so far been unsuccessful. Although transduction of NKL and 
NK92 cell lines with Mamu-KIR3DL01 or -KIR3DL05 resulted in KIR surface expression, these 
NK cell lines were not inhibited by the ligands of these KIRs (data not shown). A comparison 
between human KIR3DL1 and Mamu-KIR3DL01 transmembrane and cytoplasmic domains, 
which would be responsible for interaction with downstream effectors of ITIM signaling, reveals 
that there is approximately 25% amino acid variation between these KIR (Figure 4.1). These 
variations may cause an incompatibility between rhesus macaque KIR signaling and human cell 
lines. Ongoing work to produce chimeric KIR with extracellular domains of rhesus macaque 
KIRs and transmembrane and cytoplasmic domains of human KIR will attempt to overcome this 
obstacle and define ligands for rhesus macaque KIRs for which specific staining reagents are not 
available. 
 
 
 
Figure 4.1. Amino acid alignment of transmembrane and cytoplasmic domains of Mamu-
KIR3DL01*001 and human KIR3DL1*001.  
  
 
In addition to general screening for rhesus macaque KIR ligands, the Mamu-KIR3DL01 
ligands that we identified suggest a few more specific avenues for research. In particular, Mamu-
B*017 is a MHC class I molecule of particular interest due to its association with control of SIV 
infection (72) and is closely related to the Mamu-B ligands for Mamu-KIR3DL01. Because the 
Transmembrane Domain 
                           350 
Mamu-KIR3DL01*001 VLIGTSVAMILFT-IFFFLL 
KIR3DL1*001       I......VI...ILLL.... 
 
Cytoplasmic Domain 
                  360       370       380       390       400       410       420       430       440    
Mamu-KIR3DL01*001 HRWCSNKKNAAVMDQEPAGDRTVNREDPDEQDPQEVTYAQLDHRVLTQGKITCPSQRPRRPPTDTSVYTELPNAEPRSKVVFYP 
KIR3DL1*001       .L.................N..A.S..S.....E.........C.F..R...R.....KT.....IL.......K......SC.   
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Mamu-KIR3DL01 allotypes in this study recognized similar MHC class I molecules, Mamu-
B*17 may be recognized by one of the 23 other allotypes of Mamu-KIR3DL01 (223) or another 
related KIR. Alternatively, binding of Mamu-B*017 to KIR may be affected by SIV peptides, 
and investigation of potential Mamu-KIR3DL01 interaction with Mamu-B*017 presenting the 50 
SIV peptides that bind to Mamu-B*017 (251) would be another exciting avenue of research. 
Identification of the KIRs that recognize this protective MHC class I allotype will be very 
important in determining if Mamu-B*017-KIR interactions play a role in the viral control with 
which it is associated.   
 Analysis of viral evolution in MHC class I-defined animals that do or do not express 
Mamu-KIR3DL05 would be an interesting followup to our finding that certain Mamu-A1*002-
bound SIV peptides promote interaction with Mamu-KIR3DL05. Selective accumulation of viral 
variants in Mamu-A1*002+Mamu-KIR3DL05+ animals would warrant investigation by the 
peptide-pulse cytotoxicity assay to evaluate whether these changes were selected for by 
increasing inhibition of Mamu-KIR3DL05+ NK cells. Variants could accomplish this increased 
inhibition in two ways: by increasing the inhibitory capacity of an SIV peptide that binds to 
Mamu-A1*002 (239), or by generating a new inhibitory Mamu-A1*002-bound peptide by 
mutation in the anchor residues that are bound by this MHC class I molecule. Because this 
anchor residue pattern is well-documented for Mamu-A1*002, in silico prediction of binding to 
this MHC class I molecule may be useful to detect accumulation of such changes. These 
predictions could then be validated by stabilization of surface Mamu-A1*002 on 721.221-ICP47-
A1*002 cells as a measure of Mamu-A1*002 binding. If these inhibitory peptides are involved in 
the viral pathogenesis that leads to higher viral load in Mamu-KIR3DL05+ animals (186), one 
would expect that polymorphisms that increase the inhibitory capacity of Mamu-A1*002-bound 
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peptides would accumulate selectively in Mamu-A1*002+Mamu-KIR3DL05+ animals to inhibit 
Mamu-KIR3DL05+ NK cells and promote viral replication.  
 Unfortunately it was not possible to investigate the in vivo relevance of the most 
important inhibitory epitopes identified in this dissertation, Gag GY9 and Nef YY9. Generating 
full-length SIVmac239 with a mutation at position 8 of GY9 to any of the non-inhibitory variants 
identified (L8F, L8W, and L8Y substitutions) produces non-replicating virus (data not shown). 
Furthermore, mutation at position 7 and 8 of YY9 interferes with Nef-mediated downregulation 
of MHC class I (252). Therefore, the introduction of changes in YY9 intended to alter the 
inhibitory epitope to be non-inhibitory (I7W and R7W substitutions) into full-length SIVmac239 
would result in higher expression of the Mamu-KIR3DL05 ligand Mamu-A1*002 on the infected 
cell surface, confounding results. Nef is also responsible for downregulating other NK cell 
receptor ligands (122, 253) and substitutions at these residues of YY9 may therefore have further 
unintended effects upon NK cell activity in response to SIV-infected cells. 
Our findings, together with other recently published work identifying ligands and staining 
reagents for rhesus macaque KIRs, make it possible to follow KIR-expressing NK cell 
populations longitudinally in animals that do or do not express the ligand for a given KIR. This 
prospect is of particular interest during viral infection to monitor how KIR-expressing 
populations change, in terms of function, localization, and frequency, during the course of 
infection. Monitoring KIR-expressing NK cell populations in the gut mucosa during SIV 
infection may better characterize the role of KIR-expressing NK cell subsets in acute and chronic 
immunodeficiency virus infection, as it is obviously not possible to extensively sample gut NK 
cell populations in HIV patients.  
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The data presented in this dissertation demonstrate that rhesus macaque Mamu-
KIR3DL01 and human KIR3DL1 recognition of Bw4 ligands exhibit a distinct but overlapping 
pattern of recognition and suggests that Bw4 recognition has been maintained since the 
divergence of apes and Old World monkeys. Furthermore, I have demonstrated that the peptide 
preference of Mamu-KIR3DL05 recognition causes selective inhibition of Mamu-KIR3LD05+ 
NK cells in response to Mamu-A1*002+ cells presenting inhibitory SIV peptides. Due to the 
dominant effect of these inhibitory viral peptides, they may inhibit Mamu-KIR3DL05+ NK cells 
even when presented on the infected cell surface as part of a mixture of self and viral peptides 
and under conditions of partial MHC class I downregulation. The results of these studies, and the 
novel use of a KIR-specific antibody and ICP47-transduced peptide-pulse cytotoxicity assay, 
provide a foundation for further investigations of KIR-MHC class I interactions in SIV infection. 
The investigation of liver-resident and gut-resident NK cells that are not available for study in 
HIV patients will be essential to better understanding of the role of KIR-expressing NK cells in 
immunodeficiency virus infections. 
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Supplemental Figure 2.1. Pan-KIR2D Ab NKVFS1 stains NK cells in some rhesus macaques. 
(A) NKVFS1 staining of singlet lymphocytes is shown versus staining for different cell-type 
markers. (B) NKVFS1 staining of CD8+CD3+ and CD8+NKG2A+ cells. (C) NKVFS1 staining in 
the four CD3-NKG2A+ NK cell populations defined by CD16 and CD56 expression. Results 
representative of staining of PBMC from 3 animals.  
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Supplemental Figure 3.1. Stabilization of cell surface Mamu-A1*002 expression by peptide 
pulse. 721.221-ICP47-A1*002 cells pulsed with the Mamu-A1*002-binding SIVmac239 
peptides indicated were stained with pan-MHC class I antibody clone W6/32 to evaluate Mamu-
A1*002 surface stabilization. Data summarized from two independent experiments and error 
bars indicate +1 SD. 
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Supplemental Figure 3.2. Lysis of peptide-pulsed cells by Mamu-KIR3DL05- NK cells.  
Mamu-KIR3DL05- NK cells were coincubated at a 5:1 E:T ratio with 721.221-ICP47-A1*002 
cells pulsed with the Mamu-A1*002-binding SIVmac239 peptides indicated. Peptides are 
ordered by affinity of peptide binding to Mamu-A1*002 from highest affinity to lowest and 
defined CD8+ T cell epitopes are shown in purple. Killing of target cells was evaluated by 
release of CAM from target cells into the culture supernatant. Compiled results are from 
experiments with expanded cells from three different animals and error bars indicate + 1 SD. 
GY9 2N9G is a non-A1*002-binding peptide control. 
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Supplemental Figure 3.3. Stabilization of cell surface Mamu-A1*002 by peptide pulse. 
721.221-ICP47-A1*002 cells pulsed with the Mamu-A1*002-binding SIVmac239 peptide 
variants indicated were stained with pan-MHC class I antibody clone W6/32 to evaluate Mamu-
A1*002 surface stabilization. Data representative of at least two independent experiments. 
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Supplemental Figure 3.4. Abrogation of GY9 inhibitory capacity by aromatic amino acid 
substitutions at residue 8. (A) Mamu-KIR3DL05- and -KIR3DL05+ NK cells were coincubated 
with 721.221-ICP47-A1*002 cells pulsed with variants of GY9. Killing of target cells at the 
indicated E:T ratios was evaluated by release of CAM from target cells into the culture 
supernatant. Results are representative of those obtained with expanded cells from two different 
animals and the compiled results from these animals are presented in (B). Error bars indicate + 1 
SD. Asterisks indicate a significant difference (****p<0.001 by ANOVA with Dunnett’s test) 
between coincubation with 721.221-ICP47-A1*002 cells pulsed with GY9 and those pulsed with 
the indicated GY9 variant at all E:T ratios shown. (C) Stabilization of Mamu-A1*002 on the 
721.221-ICP47-A1*002 cell surface by peptide pulsing was verified by staining with W6/32 
antibody. GY9 2N9G is a non-A1*002-binding peptide control. 
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Supplemental Figure 3.5. Stabilization of cell surface Mamu-A1*002 by peptide mixtures. 
721.221-ICP47-A1*002 cells pulsed with mixtures of two peptides at the µM concentrations 
indicated were stained with pan-MHC class I antibody clone W6/32 to evaluate Mamu-A1*002 
surface stabilization. Data representative of at least two independent experiments. 
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